<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ROSIGLITAZONE MALEATE- rosiglitazone maleateÂ tabletÂ </strong><br>West-ward Pharmaceutical Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">Â <br>These highlights do not include all the information needed to use rosiglitazone maleate tablets safely and effectively.Â  See full prescribing information for rosiglitazone maleate tablets.<br><br></span>Rosiglitazone Maleate Tablets<br><br><span class="Bold">Initial U.S. Approval: 1999</span>
</div>
<div class="Warning"><div>
<span class="Bold">WARNING:</span><h1 class="Warning"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">MYOCARDIAL ISCHEMIA</span></span></h1>
<h1 class="Warning">â—? Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients (5.1). After initiation of rosiglitazone maleate, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone maleate must be considered.</h1>
<p class="Highlighta">â—?Â RosiglitazoneÂ maleate Â is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation ofÂ rosiglitazone maleateÂ in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (4, 5.1) </p>
<p class="Highlighta">â—? A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total patients), most of which comparedÂ rosiglitazone maleateÂ to placebo, showedÂ rosiglitazone maleateÂ to be associated with an increased risk of myocardial ischemic events such as angina or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Three other studies (mean duration 41 months; 14,067 total patients), comparingÂ rosiglitazone maleateÂ to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded this risk. In their entirety, the available data on the risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> are inconclusive. (5.2) </p>
</div></div>
<div></div>
<div class="Warning"><div>
<span class="Bold">WARNING:</span><h1 class="Warning"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">MYOCARDIAL ISCHEMIA</span></span></h1>
<h1 class="Warning">â—? Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients (5.1). After initiation of rosiglitazone maleate, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone maleate must be considered.</h1>
<p class="Highlighta">â—?Â RosiglitazoneÂ maleate Â is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation ofÂ rosiglitazone maleateÂ in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (4, 5.1) </p>
<p class="Highlighta">â—? A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total patients), most of which comparedÂ rosiglitazone maleateÂ to placebo, showedÂ rosiglitazone maleateÂ to be associated with an increased risk of myocardial ischemic events such as angina or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Three other studies (mean duration 41 months; 14,067 total patients), comparingÂ rosiglitazone maleateÂ to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded this risk. In their entirety, the available data on the risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> are inconclusive. (5.2) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Rosiglitazone tabletsÂ is a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (1)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Important Limitations of Use:   (<a href="#section-1">1</a>)</p>
<ul class="Disk">
<li><p class="Highlighta">Rosiglitazone tabletsÂ should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (1.2)  (<a href="#section-1">1</a>)</p></li>
<li><p class="Highlighta">Coadministration ofÂ rosiglitazone tabletsÂ and insulin is not recommended. (1.2, 5.3)  (<a href="#section-1">1</a>)</p></li>
<li><p class="Highlighta">Use ofÂ rosiglitazone tabletsÂ with nitrates is not recommended. (1.2, 5.2)  (<a href="#section-1">1</a>)</p></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li><p class="Highlighta">Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily. (2)  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">Dose increases should be accompanied by careful monitoring for adverse events related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (2)  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">Do not initiateÂ rosiglitazone maleateÂ if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels. (2.4)  (<a href="#section-2">2</a>)</p></li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Oval film-coated tablets in the following strengths::  (<a href="#section-3">3</a>)</p>
<ul class="Disk"><li><p class="Highlighta">2Â mg, 4Â mg, and 8Â mg (3)  (<a href="#section-3">3</a>)</p></li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Initiation of rosiglitazone maleate in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, which may exacerbate or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, may occur. Combination use with insulin and use in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> NYHA Class I and II may increase risk of other cardiovascular effects. (5.1, 5.3)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Increased risk of myocardial ischemic events has been observed in a meta-analysis of 42 clinical trials (incidence rate 2% versus 1.5%). (5.2)   (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Use of rosiglitazone maleate with nitrates is not recommended. (1.2, 5.2)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Coadministration ofÂ rosiglitazone maleateÂ and insulin is not recommended. (1.2, 5.3)   (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Dose-related <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (5.4), <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (5.5), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (5.9) may occur.  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported. (5.7)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Increased incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in female patients. (5.8)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with rosiglitazone maleate or any other oral antidiabetic drug (5.2)  (<a href="#section-5">5</a>)</p></li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Common adverse reactions (&gt;5%) reported in clinical trials without regard to causality were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, injury, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (6.1)<br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp, at 732-542-1191 or FDA <br>at 1-800-FDA-1088 or <a href="#medwatch">www.fda.gov/medwatch</a>. </span> </p></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. (7.1)  (<a href="#section-7">7</a>)</p></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="XmChange">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">MYOCARDIAL ISCHEMIA</span></span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span> INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1 </span><span class="Bold">Monotherapy and Combination Therapy</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 </span><span class="Bold">Important Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span> DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span> Monotherapy</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2</span> Combination With Sulfonylurea or Metformin</a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3</span> Combination With Sulfonylurea Plus Metformin</a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4</span> Specific Patient Populations</a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span> DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span> CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span> WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2</span> <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3</span> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> During Coadministration of AVANDIA With Insulin</a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6</span> Hepatic Effects</a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7</span> <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8</span> <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9</span> Hematologic Effects</a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and Blood Glucose Control</a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11</span> Ovulation</a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span> ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1</span> Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2</span> Laboratory Abnormalities</a></h2>
<h2><a href="#section-6.3" class="toc"><span class="Bold">6.3</span> Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span> DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1</span> CYP2C8 Inhibitors and Inducers</a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span> USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1</span> Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2</span> Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3</span> Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4</span> Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5</span> Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span> OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span> DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span> CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1</span> Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2</span> Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3</span> Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc"><span class="Bold">12.4</span> Drug-Drug Interactions</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span> NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1</span> Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.2</span> Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span> CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1</span> Monotherapy</a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2</span> Combination With Metformin or Sulfonylurea</a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3</span> Combination With Sulfonylurea Plus Metformin</a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">15</span> REFERENCES</a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16</span> HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17</span> PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1</span> Patient Advice</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5"></a><a name="section-1"></a><p></p>
<h1 style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">MYOCARDIAL ISCHEMIA</span></span></h1>
<p class="First">â—? Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients [see Warnings and Precautions (5.1)]. After initiation of rosiglitazone maleate, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction ofÂ rosiglitazone maleateÂ must be considered.</p>
<p>â—? Rosiglitazone MaleateÂ is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation ofÂ rosiglitazone maleateÂ in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. <span class="Italics">[SeeÂ <a href="#LINK_23eb1117-fb97-121a-ab08-38165cfb7f00">Contraindications (4)</a>Â  and <a href="#LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544">Warnings and Precautions (5.1</a>Â ).]</span></p>
<p>â—? A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total patients), most of which comparedÂ rosiglitazone maleateÂ to placebo, showedÂ rosiglitazone maleateÂ to be associated with an increased risk of myocardial ischemic events such as angina or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Three other studies (mean duration 41 months; 14,067 total patients), comparingÂ rosiglitazone maleateÂ to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded this risk. In their entirety, the available data on the risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> are inconclusive. <span class="Italics">[See <a href="#LINK_76f1078b-bdd3-e622-62ba-41a4be0b6fa9">Warnings and Precautions (5.2)</a>Â .]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_22e569b9-ba27-2a36-a082-97aa56f8a5d0"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span> INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_be3d3745-59cb-9ac4-28b4-8e7ad14232b2"></a><a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1 </span><span class="Bold">Monotherapy and Combination Therapy</span>
</h2>
<p class="First">Rogislitazone tablets areÂ indicated as an adjunct to diet and exercise to improve glycemic control in adults with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_1a51f93b-47fe-4e51-cea7-a4ff593de292"></a><a name="section-1.2"></a><p></p>
<h2>
<span class="Bold">1.2 </span><span class="Bold">Important Limitations of Use</span>
</h2>
<ul class="Disk">
<li><p class="First">Due to its mechanism of action, Rosiglitazone maleate is active only in the presence of endogenous insulin. Therefore,Â Rosiglitazone maleateÂ should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p></li>
<li><p class="First">The coadministration ofÂ RosiglitazoneÂ maleateÂ and insulin is not recommended. </p></li>
<li><p class="First">The use ofÂ Rosiglitazone maleateÂ with nitrates is not recommended.</p></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_60ae6558-bf00-b84d-b566-4b5206b56662"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span> DOSAGE AND ADMINISTRATION</h1>
<p class="First">The management of antidiabetic therapy should be individualized. All patients should startÂ rosiglitazone maleate tabletsÂ at the lowest recommended dose. Further increases in the dose ofÂ rosiglitazone maleate tabletsÂ should be accompanied by careful monitoring for adverse events related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> <span class="Italics">[see <a href="#LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544">Boxed Warning and Warnings and Precautions (5.1)</a>Â ]</span>.</p>
<p>RosiglitazoneÂ maleate tabletsÂ may be administered at a starting dose of 4Â mg either as a single daily dose or in 2 divided doses. For patients who respond inadequately following 8 to 12Â weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to 8Â mg daily as monotherapy or in combination with metformin, sulfonylurea, or sulfonylurea plus metformin. Reductions in glycemic parameters by dose and regimen are described under <span class="Italics"><a href="#LINK_1cdd11fd-33e1-4301-1b7e-f971f309bde7">Clinical Studies (14.1)</a></span>Â .Â Rosiglitazone maleateÂ tabletsÂ may be taken with or without food.</p>
<p>The total daily dose ofÂ rosiglitazone maleate tabletsÂ should not exceed 8Â mg.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3c8c2a14-54a8-ec4f-4d46-4cdcd7375a56"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span> Monotherapy</h2>
<p class="First">The usual starting dose ofÂ rosiglitazone maleate tabletsÂ is 4Â mg administered either as a single dose once daily or in divided doses twice daily. In clinical trials, the 4-mg twice-daily regimen resulted in the greatest reduction in FPG and hemoglobin A1c (HbA1c).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_27e07fb6-e436-e037-c26c-c991a6cb03bf"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2</span> Combination With Sulfonylurea or Metformin</h2>
<p class="First">WhenÂ rosiglitazone maleate tabletsÂ is added to existing therapy, the current dose(s) of the agent(s) can be continued upon initiation of therapy with rosiglitazone maleate tablets.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_20cdd8fe-efb4-4304-1686-3fe6825b1b58"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold"><span class="Underline">Sulfonylurea</span></span></h3>
<p class="First">When used in combination with sulfonylurea, the usual starting dose ofÂ Rosiglitazone maleate Â is 4Â mg administered as either a single dose once daily or in divided doses twice daily. If patients report <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, the dose of the sulfonylurea should be decreased.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_86d10a05-ec1a-4a86-2987-a55bf34240ee"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold"><span class="Underline">Metformin</span></span></h3>
<p class="First">The usual starting dose ofÂ Rosiglitazone MaleateÂ in combination with metformin is 4Â mg administered as either a single dose once daily or in divided doses twice daily. It is unlikely that the dose of metformin will require adjustment due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> during combination therapy with Rosiglitazone Maleate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_ecc61b0a-ea5b-4a01-7ea0-32fac307ec70"></a><a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.3</span> Combination With Sulfonylurea Plus Metformin</h2>
<p class="First">The usual starting dose ofÂ rosiglitazone maleate tabletsÂ in combination with a sulfonylurea plus metformin is 4Â mg administered as either a single dose once daily or divided doses twice daily. If patients report <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, the dose of the sulfonylurea should be decreased.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_bfe6c35d-8714-cae8-cb31-0820c76dfaf0"></a><a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.4</span> Specific Patient Populations</h2>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_7553ca24-aec4-4089-48aa-6adc8d8961ac"></a><a name="section-2.4.1"></a><p></p>
<h3><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></h3>
<p class="First">No dosage adjustment is necessary whenÂ Rosiglitazone maleateÂ is used as monotherapy in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Since metformin is contraindicated in such patients, concomitant administration of metformin andÂ Rosiglitazone maleateÂ is also contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_f46e81a4-9167-7c3d-7bbb-0228bcf56c7f"></a><a name="section-2.4.2"></a><p></p>
<h3><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></h3>
<p class="First">Liver enzymes should be measured prior to initiating treatment with rosiglitazone maleate. Therapy with rosiglitazone maleateshould not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal at start of therapy). After initiation of rosiglitazone maleate, liver enzymes should be monitored periodically per the clinical judgment of the healthcare professional. <span class="Italics">[SeeÂ <a href="#LINK_3007c3b3-1d56-55e4-c4cd-d88a96d20e37">Warnings and Precautions (5.6)</a>Â  and <a href="#LINK_24e5708b-2668-6b2a-f15f-3a19160f0b01">Clinical Pharmacology (12.3)</a>Â .]</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d69c998a-5d1e-45af-7aad-9e62aa4876b9"></a><a name="section-2.4.3"></a><p></p>
<h3><span class="Bold"><span class="Underline">Pediatric</span></span></h3>
<p class="First">Data are insufficient to recommend pediatric use of rosiglitazone maleate <span class="Italics">[see <a href="#LINK_ef02fbcb-cdca-0db2-2e37-4d15a5e4d63d">Use in Specific Populations (8.4</a>Â )]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_3d7ee3ad-8ecd-4156-9a2f-f0a2b1d02b1c"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span> DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Oval film-coated tablet contains rosiglitazone as the maleate as follows::</p>
<ul class="Disk">
<li><p class="First">2 mg - Pink oval film coated tablets, engraved with W41.</p></li>
<li><p class="First">4 mg - Orange oval film coated tablets, engraved with W42.</p></li>
<li><p class="First">8 mg - Brick red oval film coated tablets, engraved with W43.</p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_23eb1117-fb97-121a-ab08-38165cfb7f00"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span> CONTRAINDICATIONS</h1>
<p class="First">Initiation ofÂ rosiglitazone maleateÂ in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed Warning</a>Â ]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_b20d062a-a837-6752-26ca-e7c6e5996698"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span> WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Rosiglitazone maleate, like other thiazolidinediones, alone or in combination with other antidiabetic agents, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which may exacerbate or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone must be considered <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed Warning</a>Â ]</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) NYHA Class I and II treated withÂ Rosiglitazone maleateÂ have an increased risk of cardiovascular events. A 52-week, double-blind, placebo-controlled echocardiographic study was conducted in 224 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and NYHA ClassÂ I or II CHF (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤45%) on background antidiabetic and CHF therapy. An independent committee conducted a blinded evaluation of fluid-related events (including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>) and cardiovascular hospitalizations according to predefined criteria (adjudication). Separate from the adjudication, other cardiovascular adverse events were reported by investigators. Although no treatment difference in change from baseline of <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fractions</span> was observed, more cardiovascular adverse events were observed following treatment with rosiglitazone maleate compared to placebo during the 52-week study. (See Table 1.)</p>
<table frame="border" rules="all">
<caption><span>Table 1. Emergent Cardiovascular Adverse Events in Patients With <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (NYHA Class I and II) Treated WithÂ Rosiglitazone Maleate TabletsÂ or Placebo (in Addition to Background Antidiabetic and CHF Therapy) </span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â <span class="Bold">Events</span>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">Rosiglitazone <br>maleate tablets</span></p></td>
<td align="center" valign="top">Â <span class="Bold">Placebo</span>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â N = 110<p class="First">n (%)</p>
</td>
<td align="center" valign="top">Â N = 114<p class="First">n (%)</p>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Adjudicated</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></td>
<td align="center" valign="top"><p class="First">5 (5%)</p></td>
<td align="center" valign="top">Â 4 (4%)</td>
</tr>
<tr>
<td valign="top">Â CHF worsening</td>
<td align="center" valign="top">Â 7 (6%)</td>
<td align="center" valign="top">Â  4 (4%)</td>
</tr>
<tr>
<td valign="top">Â â€“ with overnight hospitalization</td>
<td align="center" valign="top"><p class="First">5 (5%)</p></td>
<td align="center" valign="top">Â 4 (4%)</td>
</tr>
<tr>
<td valign="top">Â â€“ without overnight hospitalization</td>
<td align="center" valign="top">Â 2 (2%)</td>
<td align="center" valign="top">Â 0 (0%)</td>
</tr>
<tr>
<td valign="top">Â New or worsening <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td align="center" valign="top">Â 28 (25%)</td>
<td align="center" valign="top">Â 10 (9%)</td>
</tr>
<tr>
<td valign="top">Â New or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
<td align="center" valign="top">Â 29 (26%)</td>
<td align="center" valign="top">Â 19 (17%)</td>
</tr>
<tr>
<td valign="top">Â Increases in CHF medication</td>
<td align="center" valign="top">Â 36 (33%)</td>
<td align="center" valign="top">Â 20 (18%)</td>
</tr>
<tr>
<td valign="top">Â Cardiovascular hospitalization<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â 21 (19%)</td>
<td align="center" valign="top">Â 15 (13%)</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Investigator-reported, non-adjudicated</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Ischemic adverse events </td>
<td align="center" valign="top">Â 10 (9%)</td>
<td align="center" valign="top"><p class="First">5 (4%)</p></td>
</tr>
<tr>
<td valign="top">Â â€“ <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></td>
<td align="center" valign="top"><p class="First">5 (5%)</p></td>
<td align="center" valign="top">Â 2 (2%)</td>
</tr>
<tr class="Last">
<td valign="top">Â â€“ Angina</td>
<td align="center" valign="top">Â 6 (5%)</td>
<td align="center" valign="top">Â 3 (3%)</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td>Â <span class="Sup">*</span> Includes hospitalization for any cardiovascular reason.</td></tr></tbody>
</table>
<p>Initiation of rosiglitazone maleateÂ in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated.Â Rosiglitazone maleateÂ is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="Italics">[See <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed Warning</a>Â .]</span></p>
<p>Patients experiencing <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndromes</span> have not been studied in controlled clinical trials. In view of the potential for development of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in patients having an acute coronary event, initiation ofÂ rosiglitazone maleateÂ is not recommended for patients experiencing an acute coronary event, and discontinuation ofÂ rosiglitazone maleateÂ during this acute phase should be considered.</p>
<p>Patients with NYHA Class III and IV cardiac status (with or without CHF) have not been studied in controlled clinical trials.Â Rosiglitazone maleateÂ is not recommended in patients with NYHA Class III and IV cardiac status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_76f1078b-bdd3-e622-62ba-41a4be0b6fa9"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2</span> <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span></h2>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_4f25b45e-acec-d4e3-d32b-8aed8611c3c7"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="Bold">Meta-Analysis of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> in a Group of 42 Clinical Trials</span></h3>
<p class="First">A meta-analysis was conducted retrospectively to assess cardiovascular adverse events reported across 42 double-blind, randomized, controlled clinical trials (mean duration 6 months).<span class="Sup">1 </span>These studies had been conducted to assess glucose-lowering efficacy in type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and prospectively planned adjudication of cardiovascular events had not occurred in the trials. Some trials were placebo-controlled and some used active oral antidiabetic drugs as controls. Placebo-controlled studies included monotherapy trials (Monotherapy withÂ rosiglitazone maleate Â versus placebo monotherapy) and add-on trials (rosiglitazone maleateÂ or placebo, added to sulfonylurea, metformin, or insulin). Active control studies included monotherapy trials (monotherapy with rosiglitazone maleate versus sulfonylurea or metformin monotherapy) and add-on trials (rosiglitazone maleateÂ plus sulfonylurea orÂ rosiglitazone maleateÂ plus metformin, versus sulfonylurea plus metformin). A total of 14,237 patients were included (8,604 in treatment groups containing rosiglitazone maleate, 5,633 in comparator groups), with 4,143 patient-years of exposure toÂ rosiglitazone maleateÂ and 2,675 patient-years of exposure to comparator. Myocardial ischemic events included <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris aggravated</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316995" conceptname="Coronary occlusion">coronary artery occlusion</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4134723" conceptname="Coronary artery thrombosis">coronary thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, and <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disorder</span>. In this analysis, an increased risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> withÂ rosiglitazone maleateÂ versus pooled comparators was observed (2%Â rosiglitazone maleateÂ versus 1.5% comparators, odds ratio 1.4, 95% confidence interval [CI] 1.1, 1.8). An increased risk of myocardial ischemic events withÂ rosiglitazone maleateÂ was observed in the placebo-controlled studies, but not in the active-controlled studies. (See Figure 1.)</p>
<p>A greater increased risk of myocardial ischemic events was observed in studies whereÂ rosiglitazone maleateÂ was added to insulin (2.8% forÂ rosiglitazone maleateÂ plus insulin versus 1.4% for placebo plus insulin, [OR 2.1, 95% CI 0.9, 5.1]). This increased risk reflects a difference of 3 events per 100 patient-years (95% CI -0.1, 6.3) between treatment groups. <span class="Italics">[See <a href="#LINK_afe72f90-a7e0-adbd-4239-a0b80a934065">Warnings and Precautions (5.3)</a>Â .]</span></p>
<div class="Figure">
<img alt="Myocardial Ischemic Adverse Events" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-1.jpg"><p class="MultiMediaCaption">Figure 1 - Forest Plot of Odds Rations (95% Confidence Intervals) for Myocardial Ischemic Events in the Meta-Analysis of 42 Clinical Trials</p>
</div>
<p>A greater increased risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was also observed in patients who receivedÂ rosiglitazone maleateÂ and background nitrate therapy. ForÂ rosiglitazone maleateÂ (N = 361) versus control (N = 244) in nitrate users, the odds ratio was 2.9 (95% CI 1.4, 5.9), while for non-nitrate users (about 14,000 patients total), the odds ratio was 1.3 (95% CI 0.9, 1.7). This increased risk represents a difference of 12 myocardial ischemic events per 100 patient-years (95% CI 3.3, 21.4). Most of the nitrate users had established coronary heart disease. Among patients with known coronary heart disease who were not on nitrate therapy, an increased risk of myocardial ischemic events forÂ rosiglitazone maleateÂ versus comparator was not demonstrated.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_bac0d084-3738-6e74-1892-4dc2a83d1d6d"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="Bold">Myocardial Ischemic Events in Large Long-Term Prospectice Randomized Controlled Trials of rosiglitazone maleate</span></h3>
<p class="First">Data from 3 other large, long-term, prospective, randomized, controlled clinical trials ofÂ rosiglitazone maleateÂ were assessed separately from the meta-analysis. These 3 trials include a total of 14,067 patients (treatment groups containingÂ rosiglitazone maleateÂ NÂ =Â 6,311, comparator groups NÂ =Â 7,756), with patient-year exposure of 21,803 patient-years for rosiglitazone maleate and 25,998 patient-years for comparator. Duration of follow-up exceeded 3 years in each study. ADOPT (A <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Outcomes Progression Trial) was a 4- to 6-year randomized, active-controlled study in recently diagnosed patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> naÃ¯ve to drug therapy. It was an efficacy and general safety trial that was designed to examine the durability ofÂ rosiglitazone maleateÂ as monotherapy (NÂ =Â 1,456) for glycemic control in type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, with comparator arms of sulfonylurea monotherapy (NÂ =Â 1,441) and metformin monotherapy (NÂ =Â 1,454). DREAM (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Reduction Assessment with Rosiglitazone and Ramipril Medication, published report<span class="Sup">2</span>) was a 3- to 5-year randomized, placebo-controlled study in patients with impaired glucose tolerance and/or <span class="product-label-link" type="condition" conceptid="4308509" conceptname="Impaired fasting glycaemia">impaired fasting glucose</span>. It had a 2x2 factorial design, intended to evaluate the effect of rosiglitazone maleate, and separately of ramipril (an angiotensin converting enzyme inhibitor [ACEI]), on progression to overt <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. In DREAM, 2,635 patients were in treatment groups containing rosligtazone maleate, and 2,634 were in treatment groups not containing rosiglitazone maleate. Interim results have been published <span class="Sup">3</span> for RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>), an ongoing open-label, 6-year cardiovascular outcomes study in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with an average treatment duration of 3.75 years. RECORD includes patients who have failed metformin or sulfonylurea monotherapy; those who have failed metformin are randomized to receive either add-onÂ rosiglitazone maleateÂ or add-on sulfonylurea, and those who have failed sulfonylurea are randomized to receive either add-onÂ rosiglitazone maleateÂ or add-on metformin. In RECORD, a total of 2,220 patients are receiving add-on rosiglitazone maleate, and 2,227 patients are on one of the add-on regimens not containing rosiglitazone maleate.</p>
<p>For these 3 trials, analyses were performed using a composite of major adverse cardiovascular events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), referred to hereafter as MACE. This endpoint differed from the meta-analysisâ€™ broad endpoint of myocardial ischemic events, more than half of which were angina. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> included adjudicated fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> plus <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. As shown in Figure 2, the results for the 3 endpoints (MACE, MI, and Total Mortality) were not statistically significantly different betweenÂ rosiglitazone maleateÂ and comparators.</p>
<div class="Figure">
<img alt="Figure 2 - Hazard Ratios" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-2.jpg"><p class="MultiMediaCaption">Figure 2. Hazard Ratios
for the Risk of MACE (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>,
or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>), <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Total Mortality With Rosiglitazone Maleate
Compared With a Control Group</p>
</div>
<p>In preliminary analyses of the DREAM trial, the incidence of cardiovascular events was higher among subjects who receivedÂ rosiglitazone maleateÂ in combination with ramipril than among subjects who received ramipril alone, as illustrated in Figure 2. This finding was not confirmed in ADOPT and RECORD (active-controlled trials in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) in which 30% and 40% of patients respectively, reported ACE-inhibitor use at baseline.</p>
<p>In their entirety, the available data on the risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> are inconclusive. Definitive conclusions regarding this risk await completion of an adequately-designed cardiovascular outcome study.</p>
<p>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with AVANDIA or any other oral antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_afe72f90-a7e0-adbd-4239-a0b80a934065"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3</span> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> During Coadministration of AVANDIA With Insulin</h2>
<p class="First">In studies in whichÂ rosiglitazone maleateÂ was added to insulin, rosiglitazone maleate increased the risk of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. (See Table 2.) Coadministration ofÂ rosiglitazone maleateÂ and insulin is not recommended. <span class="Italics">[SeeÂ <a href="#LINK_1a51f93b-47fe-4e51-cea7-a4ff593de292">Indications and Usage (1.2)</a>Â  and <a href="#LINK_b20d062a-a837-6752-26ca-e7c6e5996698">Warnings and Precautions (5.1, 5.2)</a>Â .]</span></p>
<p>In five, 26-week, controlled, randomized, double-blind trials which were included in the meta-analysis <span class="Italics">[seeÂ <a href="#LINK_76f1078b-bdd3-e622-62ba-41a4be0b6fa9">Warnings and Precautions (5.2)</a>Â  ]</span>, patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus were randomized to coadministration of AVANDIA and insulin (NÂ =Â 867) or insulin (NÂ =Â 663). In these 5 trials,Â rosiglitazone maleateÂ was added to insulin. These trials included patients with long-standing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (median duration of 12 years) and a high prevalence of pre-existing medical conditions, including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, vascular disease, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The total number of patients with emergent <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> was 21 (2.4%) and 7 (1.1%) in theÂ rosiglitazone maleateÂ plus insulin and insulin groups, respectively. The total number of patients with emergent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was 24 (2.8%) and 9 (1.4%) in theÂ rosiglitazone maleateÂ plus insulin and insulin groups, respectively (OR 2.1 [95% CI 0.9, 5.1]). Although the event rate for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was low in the studied population, consistently the event rate was 2-fold or higher with coadministration ofÂ rosiglitazone maleateÂ and insulin. These cardiovascular events were noted at both the 4Â mg and 8Â mg daily doses of rosiglitazone maleate. (See Table 2.)</p>
<table frame="border" rules="all">
<caption><span>Table 2. Occurrence of Cardiovascular Events in 5 Controlled Trials of Addition ofÂ Rosiglitazone MaleateÂ to Established Insulin Treatment</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="bottom">Â  <p class="First"><span class="Bold">Event*</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Rosiglitazone Maleate +Â Insulin</span></p>
<p><span class="Bold">(nÂ =Â 867)</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td align="center" valign="top">
<p class="First">Â Â  <span class="Bold">Insulin</span></p>
<p><span class="Bold">(nÂ =Â 663)</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></td>
<td align="center" valign="top">Â  21 (2.4%)</td>
<td align="center" valign="top">Â 7 (1.1%)</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span></td>
<td align="center" valign="top">Â  24 (2.8%)</td>
<td align="center" valign="top"><p class="First">9 (1.4%)</p></td>
</tr>
<tr>
<td valign="top">Composite of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></td>
<td align="center" valign="top">Â  10 (1.2%)</td>
<td align="center" valign="top">Â 5 (0.8%)</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center" valign="top">Â  5 (0.6%)</td>
<td align="center" valign="top">Â 4 (0.6%)</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></td>
<td align="center" valign="top">Â  4 (0.5%)</td>
<td align="center" valign="top"><p class="First">1 (0.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td align="center" valign="top">Â Â  4 (0.5%)</td>
<td align="center" valign="top">Â 1 (0.2%)</td>
</tr>
<tr class="Last">
<td valign="top">All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></td>
<td align="center" valign="top">Â  6 (0.7%)</td>
<td align="center" valign="top">Â 1 (0.2%)</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td>Â *Events are not exclusive; i.e., a patient with a cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> would be counted in 4 event categories (<span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>).</td></tr></tbody>
</table>
<p>In a sixth, 24-week, controlled, randomized, double-blind trial ofÂ rosiglitaszone maleateÂ and insulin coadministration, insulin was added to AVANDAMET<span class="Sup">Â®</span> (rosiglitazone maleate and metformin HCl) (nÂ =Â 161) and compared to insulin plus placebo (nÂ =Â 158), after a single-blind 8-week run-in with AVANDAMET. Patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> requiring pharmacologic therapy and those with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> were excluded at baseline and during the run-in period. In the group receiving AVANDAMET plus insulin, there was one myocardial ischemic event and one <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. No <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was observed in the insulin group, and no <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> was reported in either treatment group.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_00c9e447-1728-48a5-c3b2-ea3d0efb73ae"></a><a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.4</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Rosiglitazone maleateÂ should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. In a clinical study in healthy volunteers who received 8Â mg ofÂ rosiglitazone maleateÂ once daily for 8Â weeks, there was a statistically significant increase in median plasma volume compared to placebo.</p>
<p>Since thiazolidinediones, including rosiglitazone, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>,Â rosiglitazone maleateÂ should be used with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed Warning</a>Â , <a href="#LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544">Warnings and Precautions (5.1</a>Â ), and <a href="#LINK_bab54fde-a37a-4ea3-959c-fb5823792874">Patient Counseling Information (17.1)</a>Â ]</span>.</p>
<p>In controlled clinical trials of patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, mild to moderate <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in patients treated with rosiglitazone maleate, and may be dose related. Patients with ongoing <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> were more likely to have adverse events associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> if started on combination therapy with insulin andÂ rosiglitazone maleateÂ <span class="Italics">[see <a href="#LINK_5bcf47ee-3dfc-4992-1ef7-2b1485b987e1">Adverse Reactions (6.1)]</a>Â </span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_5aa4d938-7a07-718a-dbe5-8e50414c381a"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Dose-related <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was seen withÂ rosiglitazone maleateÂ alone and in combination with other hypoglycemic agents (Table 3). The mechanism of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> is unclear but probably involves a combination of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and fat accumulation.</p>
<p>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed Warning</a>Â ]</span>.</p>
<table frame="border" rules="all">
<caption><span>Table 3. Weight Changes (kg) From Baseline at Endpoint During Clinical Trials</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" colspan="2" valign="top">Â <span class="Bold">Control Group</span>
</td>
<td align="center" valign="top">Â <span class="Bold">Rosiglitazone<br>maleate</span><p class="First"><span class="Bold">4 mg</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Rosiglitazone<br>maleate</span></p>
<p><span class="Bold">8 mg</span></p>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Monotherapy</span>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">Duration</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Median</span></p>
<p><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentile)</span></p>
</td>
<td align="center" valign="top">Â <span class="Bold">Median</span><p class="First"><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentile)</span></p>
</td>
<td align="center" valign="top">Â <span class="Bold">Median</span><p class="First"><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentile)</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â 26 weeks</td>
<td align="center" valign="top">Â placebo</td>
<td align="center" valign="top">Â -0.9 (-2.8, 0.9)<p class="First">nÂ =Â 210</p>
</td>
<td align="center" valign="top">
<p class="First">1.0 (-0.9, 3.6)</p>
<p>nÂ =Â 436</p>
</td>
<td align="center" valign="top">
<p class="First">3.1 (1.1, 5.8)</p>
<p>nÂ =Â 439</p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First">52 weeks</p></td>
<td align="center" valign="top">Â  sulfonylurea</td>
<td align="center" valign="top">Â 2.0 (0, 4.0)<p class="First">nÂ =Â 173</p>
</td>
<td align="center" valign="top">Â  2.0 (-0.6, 4.0)<p class="First">nÂ =Â 150</p>
</td>
<td align="center" valign="top">Â  2.6 (0, 5.3)<p class="First">nÂ =Â 157</p>
</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Combination therapy</span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Sulfonylurea</td>
<td align="center" valign="top">Â 24-26 weeks</td>
<td align="center" valign="top"><p class="First">sulfonylurea</p></td>
<td align="center" valign="top">Â  0 (-1.0, 1.3)<p class="First">nÂ =Â 1,155</p>
</td>
<td align="center" valign="top">Â  2.2 (0.5, 4.0)<p class="First">nÂ =Â 613</p>
</td>
<td align="center" valign="top">Â  3.5 (1.4, 5.9)<p class="First">nÂ =Â 841</p>
</td>
</tr>
<tr>
<td valign="top">Metformin</td>
<td align="center" valign="top">Â 26 weeks</td>
<td align="center" valign="top"><p class="First">metformin</p></td>
<td align="center" valign="top">Â -1.4 (-3.2, 0.2)<p class="First">nÂ =Â 175</p>
</td>
<td align="center" valign="top">Â 0.8 (-1.0, 2.6)<p class="First">nÂ =Â 100</p>
</td>
<td align="center" valign="top">Â 2.1 (0, 4.3)<p class="First">nÂ =Â 184</p>
</td>
</tr>
<tr>
<td valign="top">Insulin</td>
<td align="center" valign="top"><p class="First">26 weeks</p></td>
<td align="center" valign="top">Â insulin</td>
<td align="center" valign="top">Â 0.9 (-0.5, 2.7)<p class="First">nÂ =Â 162</p>
</td>
<td align="center" valign="top">Â 4.1 (1.4, 6.3)<p class="First">nÂ =Â 164</p>
</td>
<td align="center" valign="top">Â 5.4 (3.4, 7.3)<p class="First">nÂ =Â 150</p>
</td>
</tr>
<tr class="Last">
<td valign="top">Â Sulfonylurea + metformin</td>
<td align="center" valign="top">Â 26 weeks</td>
<td align="center" valign="top">Â sulfonylurea + metformin</td>
<td align="center" valign="top">Â 0.2 (-1.2, 1.6)<p class="First">nÂ =Â 272</p>
</td>
<td align="center" valign="top">Â 2.5 (0.8, 4.6)<p class="First">nÂ =Â 275</p>
</td>
<td align="center" valign="top">
<p class="First">4.5 (2.4, 7.3)</p>
<p>nÂ =Â 276</p>
</td>
</tr>
</tbody>
</table>
<p>In a 4- to 6-year, monotherapy, comparative trial (ADOPT) in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> not previously treated with antidiabetic medication <span class="Italics">[see <a href="#LINK_1cdd11fd-33e1-4301-1b7e-f971f309bde7">Clinical Studies (14.1)</a>Â ]</span>, the median weight change (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentiles) from baseline at 4 years was 3.5 kg (0.0, 8.1) for rosiglitazone maleate, 2.0 kg (-1.0, 4.8) for glyburide, and -2.4 kg (-5.4, 0.5) for metformin.</p>
<p>In a 24-week study in pediatric patients aged 10 to 17Â years treated withÂ rosiglitazone maleateÂ 4 to 8Â mg daily, a median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 2.8Â kg (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentiles: 0.0, 5.8) was reported.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_3007c3b3-1d56-55e4-c4cd-d88a96d20e37"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6</span> Hepatic Effects</h2>
<p class="First">Liver enzymes should be measured prior to the initiation of therapy with rosiglitazone maleate in all patients and periodically thereafter per the clinical judgment of the healthcare professional. Therapy withÂ rosiglitazone maleateÂ should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt;2.5X upper limit of normal). Patients with mildly elevated liver enzymes (ALT levels â‰¤âˆ’2.5X upper limit of normal) at baseline or during therapy withÂ rosiglitazone maleateÂ should be evaluated to determine the cause of the liver enzyme elevation. Initiation of, or continuation of, therapy withÂ rosiglitazone maleateÂ in patients with mild liver enzyme elevations should proceed with caution and include close clinical follow-up, including liver enzyme monitoring, to determine if the liver enzyme elevations resolve or worsen. If at any time ALT levels increase to &gt;3X the upper limit of normal in patients on therapy with rosiglitazone maleate, liver enzyme levels should be rechecked as soon as possible. If ALT levels remain &gt;3X the upper limit of normal, therapy withÂ rosiglitazone maleateÂ should be discontinued.</p>
<p>If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy withÂ rosiglitazone maleateÂ should be guided by clinical judgment pending laboratory evaluations. If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is observed, drug therapy should be discontinued. <span class="Italics">[See <a href="#LINK_9166948a-6df4-8abb-9847-32fd91e18cbd">Adverse Reactions (6.2, 6.3).]</a>Â </span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_0132b100-cea3-4588-8298-b68a0e1092b5"></a><a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.7</span> <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported in postmarketing experience in some diabetic patients who were takingÂ rosiglitazone maleateÂ or another thiazolidinedione. Some patients presented with <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination. Most patients had <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> at the time <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> was diagnosed. Some patients had improvement in their <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> after discontinuation of their thiazolidinedione. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should have regular eye exams by an ophthalmologist, per the Standards of Care of the American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association. Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patientâ€™s underlying medications or other physical findings. <span class="Italics">[See <a href="#LINK_5bcf47ee-3dfc-4992-1ef7-2b1485b987e1">Adverse Reactions (6.1)</a>Â .]</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_30426289-7989-3fd2-ca5e-67a884eb8dce"></a><a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.8</span> <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></h2>
<p class="First">In a 4- to 6-year comparative study (ADOPT) of glycemic control with monotherapy in drug-naÃ¯ve patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, an increased incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was noted in female patients taking rosiglitazone maleate. Over the 4- to 6-year period, the incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in females was 9.3% (60/645) forÂ rosiglitazone maleateÂ versus 3.5% (21/605) for glyburide and 5.1% (30/590) for metformin. This increased incidence was noted after the first year of treatment and persisted during the course of the study. The majority of the <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in the women who receivedÂ rosiglitazone maleateÂ occurred in the upper arm, hand, and foot. These sites of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> are different from those usually associated with postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (e.g., hip or spine). No increase in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> rates was observed in men treated with rosiglitazone maleate. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered in the care of patients, especially female patients, treated with rosiglitazone maleate, and attention given to assessing and maintaining bone health according to current standards of care.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_f2e16ca3-6f63-4957-bd9e-d05fda7b5ff6"></a><a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.9</span> Hematologic Effects</h2>
<p class="First">Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with rosiglitazone maleate<span class="Italics">[see <span class="Italics"><a href="#LINK_a8900871-1bc1-d1b2-6f9f-1686aeffb638">Adverse Reactions (6.2)]</a></span><a href="#LINK_a8900871-1bc1-d1b2-6f9f-1686aeffb638">.Â </a>Â </span>The observed changes may be related to the increased plasma volume observed with treatment with rosiglitazonemaleate.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_b1bcbd7e-bdc2-452d-0da7-625bbc701fbb"></a><a name="section-5.10"></a><p></p>
<h2>
<span class="Bold">5.10</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and Blood Glucose Control</h2>
<p class="First">Patients receivingÂ rosiglitazone maleateÂ in combination with other hypoglycemic agents may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and a reduction in the dose of the concomitant agent may be necessary.</p>
<p>Periodic fasting blood glucose and HbA1c measurements should be performed to monitor therapeutic response.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_c3f4cd6e-19cf-4b19-e48b-f480afa9bfb1"></a><a name="section-5.11"></a><p></p>
<h2>
<span class="Bold">5.11</span> Ovulation</h2>
<p class="First">Therapy with rosiglitazone maleate, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while takingÂ rosiglitazone maleateÂ <span class="Italics">[see <a href="#LINK_f91f98d1-5bbc-c249-db3d-dab583e5d15e">Use in Specific Populations (8.1</a>Â )]</span>. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical studies; therefore, the frequency of this occurrence is not known.</p>
<p>Although hormonal imbalance has been seen in preclinical studies <span class="Italics">[see <a href="#LINK_9f4c471a-9bbe-0b8d-3b72-260ce0b48dfa">Nonclinical Toxicology (13.1</a>Â )]</span>, the clinical significance of this finding is not known. If unexpected menstrual dysfunction occurs, the benefits of continued therapy withÂ rosiglitazone maleateÂ should be reviewed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_9166948a-6df4-8abb-9847-32fd91e18cbd"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span> ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_5bcf47ee-3dfc-4992-1ef7-2b1485b987e1"></a><a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1</span> Clinical Trial Experience</h2>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_574b4047-d89d-7761-2907-07b94f35be46"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Adult</span></h3>
<p class="First">In clinical trials, approximately 9,900Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with rosiglitazone maleate.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_329ecb77-5437-dda9-ae28-209ad1004122"></a><a name="section-6.1.1.1"></a><p></p>
<h4>Short-Term Trials ofÂ Rosiglitazone MaleateÂ as Monotherapy and in Combination With Other Hypoglycemic Agents</h4>
<p class="First">The incidence and types of adverse events reported in short-term clinical trials ofÂ rosiglitazone maleateÂ as monotherapy are shown in Table 4.</p>
<table frame="border" rules="all">
<caption><span>Table 4. Adverse Events (â‰¥5% in Any Treatment Group) Reported by Patients in Short-Term<span class="Sup">*</span> Double-Blind Clinical Trials With Rosiglitazone Maleate as Monotherapy</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="bottom">Â <span class="Bold">Preferred Term</span>
</td>
<td align="center" valign="bottom">Â <span class="Bold">Rosiglitazone<br>maleate<br>Â Monotherapy</span>
</td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
<td align="center" valign="bottom">Â <span class="Bold">Metformin</span>
</td>
<td align="center" valign="bottom">Â <p class="First"><span class="Bold">Sulfonylureas<span class="Sup">â€ </span></span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â NÂ =Â 2,526</td>
<td align="center" valign="top">Â NÂ =Â 601</td>
<td align="center" valign="top">Â  NÂ =Â 225</td>
<td align="center" valign="top">Â  NÂ =Â 626</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td align="center" valign="top">Â <span class="Bold">%</span>
</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center" valign="top">Â 9.9</td>
<td align="center" valign="top"><p class="First">8.7</p></td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top">Â 7.3</td>
</tr>
<tr>
<td valign="top"><p class="First">Injury</p></td>
<td align="center" valign="top">Â 7.6</td>
<td align="center" valign="top"><p class="First">4.3</p></td>
<td align="center" valign="top"><p class="First">7.6</p></td>
<td align="center" valign="top"><p class="First">6.1</p></td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">Â 5.9</td>
<td align="center" valign="top"><p class="First">5.0</p></td>
<td align="center" valign="top"><p class="First">8.9</p></td>
<td align="center" valign="top">Â 5.4</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td align="center" valign="top">Â 4.0</td>
<td align="center" valign="top">Â 3.8</td>
<td align="center" valign="top">Â 4.0</td>
<td align="center" valign="top">Â 5.0</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td align="center" valign="top">Â 3.9</td>
<td align="center" valign="top">Â 5.7</td>
<td align="center" valign="top">Â 4.4</td>
<td align="center" valign="top">Â 8.1</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td align="center" valign="top">Â 3.6</td>
<td align="center" valign="top">Â 5.0</td>
<td align="center" valign="top">Â 4.0</td>
<td align="center" valign="top">Â 1.9</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td align="center" valign="top">Â 3.2</td>
<td align="center" valign="top"><p class="First">4.5</p></td>
<td align="center" valign="top">Â 5.3</td>
<td align="center" valign="top">Â 3.0</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="top">Â 2.3</td>
<td align="center" valign="top">Â 3.3</td>
<td align="center" valign="top">Â 15.6</td>
<td align="center" valign="top"><p class="First">3.0</p></td>
</tr>
<tr class="Last">
<td valign="top"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td align="center" valign="top">Â 0.6</td>
<td align="center" valign="top">Â 0.2</td>
<td align="center" valign="top"><p class="First">1.3</p></td>
<td align="center" valign="top">Â 5.9</td>
</tr>
</tbody>
<tbody class="Headless">
<tr class="First"><td>
<span class="Sup">*</span> Short-term trials ranged from 8 weeks to 1 year.</td></tr>
<tr class="Last"><td>
<span class="Sup">â€ </span> Includes patients receiving glyburide (NÂ =Â 514), gliclazide (NÂ =Â 91), or glipizide (NÂ =Â 21).</td></tr>
</tbody>
</table>
<p>Overall, the types of adverse reactions without regard to causality reported whenÂ rosiglitazone maleateÂ was used in combination with a sulfonylurea or metformin were similar to those during monotherapy with rosiglitazone maleate.</p>
<p>Events of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> tended to be reported more frequently at higher doses, and were generally mild to moderate in severity and usually did not require discontinuation of treatment with rosiglitazone maleate.</p>
<p>In double-blind studies, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was reported in 1.9% of patients receivingÂ rosiglitazone maleateÂ as monotherapy compared to 0.7% on placebo, 0.6% on sulfonylureas, and 2.2% on metformin. Reports of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> were greater in patients treated with a combination of AVANDIA and metformin (7.1%) and with a combination of AVANDIA and a sulfonylurea plus metformin (6.7%) compared to monotherapy with Arosiglitazone maleateÂ or in combination with a sulfonylurea (2.3%). Lower pre-treatment hemoglobin/hematocrit levels in patients enrolled in the metformin combination clinical trials may have contributed to the higher reporting rate of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in these studies <span class="Italics">[see <span class="Italics"><a href="#LINK_a8900871-1bc1-d1b2-6f9f-1686aeffb638">Adverse Reactions (6.2)]</a></span><a href="#LINK_a8900871-1bc1-d1b2-6f9f-1686aeffb638">.</a>Â </span></p>
<p>In clinical trials, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in 4.8% of patients receivingÂ rosiglitazone maleateÂ as monotherapy compared to 1.3% on placebo, 1.0% on sulfonylureas, and 2.2% on metformin. The reporting rate of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was higher for rosiglitazone maleate 8Â mg in sulfonylurea combinations (12.4%) compared to other combinations, with the exception of insulin. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> was reported in 14.7% of patients receivingÂ rosiglitazone maleateÂ in the insulin combination trials compared to 5.4% on insulin alone. Reports of new onset or exacerbation of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occurred at rates of 1% for insulin alone, and 2% (4Â mg) and 3% (8Â mg) for insulin in combination withÂ rosiglitazone maleateÂ <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed WarningÂ </a>Â and <a href="#LINK_afe72f90-a7e0-adbd-4239-a0b80a934065">Warnings and Precautions (5.3</a>Â )]</span>.</p>
<p>In controlled combination therapy studies with sulfonylureas, mild to moderate hypoglycemic symptoms, which appear to be dose related, were reported. Few patients were withdrawn for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (&lt;1%) and few episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were considered to be severe (&lt;1%). <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was the most frequently reported adverse event in the fixed-dose insulin combination trials, although few patients withdrew for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (4 of 408 forÂ rosiglitazone maleateÂ plus insulin and 1 of 203 for insulin alone). Rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, confirmed by capillary blood glucose concentration â‰¤50Â mg/dL, were 6% for insulin alone and 12% (4Â mg) and 14% (8Â mg) for insulin in combination with rosiglitazone maleate. <span class="Italics">[See <a href="#LINK_b1bcbd7e-bdc2-452d-0da7-625bbc701fbb">Warnings and Precautions (5.10)</a>Â .]</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_ce807370-1748-10ff-4eec-f0a164a0941e"></a><a name="section-6.1.1.2"></a><p></p>
<h4><span class="Italics">Long-Term Trial ofÂ Rosiglitazone MaleateÂ as Monotherapy</span></h4>
<p class="First">A 4- to 6-year study (ADOPT) compared the use ofÂ rosiglitazone maleateÂ (n = 1,456), glyburide (n = 1,441), and metformin (nÂ =Â 1,454) as monotherapy in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who were not previously treated with antidiabetic medication. Table 5 presents adverse reactions without regard to causality; rates are expressed per 100 patient-years (PY) exposure to account for the differences in exposure to study medication across the 3 treatment groups.</p>
<p>In ADOPT, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were reported in a greater number of women treated withÂ rosiglitazone maleateÂ (9.3%, 2.7/100 patient-years) compared to glyburide (3.5%, 1.3/100 patient-years) or metformin (5.1%, 1.5/100 patient-years). The majority of the <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in the women who received rosiglitazone were reported in the upper arm, hand, and foot. <span class="Italics">[See <a href="#LINK_0132b100-cea3-4588-8298-b68a0e1092b5">Warnings and Precautions (5.7</a>Â ).]</span> The observed incidence of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> for male patients was similar among the 3 treatment groups.</p>
<table frame="border" rules="all">
<caption><span>Table 5. On-Therapy Adverse Events (â‰¥5 Events/100 Patient-Years [PY]) in Any Treatment Group Reported in a 4- to 6-Year Clinical Trial ofÂ Rosiglitazone MaleateÂ as Monotherapy (ADOPT)</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" valign="top">Â <span class="Bold">Rosiglitazone<br>Maleate</span>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">Glyburide</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First"><span class="Bold">N = 1,456</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">N = 1,441</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">N = 1,454</span></p></td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First"><span class="Bold">PY = 4,954</span></p></td>
<td align="center" valign="top">Â  <span class="Bold">PY = 4,244</span>
</td>
<td align="center" valign="top">Â <span class="Bold">PY = 4,906</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center" valign="top"><p class="First">6.3</p></td>
<td align="center" valign="top">Â  6.9</td>
<td align="center" valign="top">Â 6.6</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center" valign="top"><p class="First">5.1</p></td>
<td align="center" valign="top">Â 4.9</td>
<td align="center" valign="top">Â  5.3</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" valign="top"><p class="First">5.0</p></td>
<td align="center" valign="top"><p class="First">4.8</p></td>
<td align="center" valign="top">Â  4.2</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center" valign="top">Â 4.4</td>
<td align="center" valign="top">Â 6.0</td>
<td align="center" valign="top">Â 6.1</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center" valign="top"><p class="First">4.3</p></td>
<td align="center" valign="top">Â 5.0</td>
<td align="center" valign="top"><p class="First">4.7</p></td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td align="center" valign="top">Â 2.9</td>
<td align="center" valign="top">Â 13.0</td>
<td align="center" valign="top"><p class="First">3.4</p></td>
</tr>
<tr class="Last">
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top"><p class="First">2.5</p></td>
<td align="center" valign="top"><p class="First">3.2</p></td>
<td align="center" valign="top">Â 6.8</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_a38c12e5-b8e2-48b4-9c8e-68cab26ff529"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Pediatric</span></h3>
<p class="First">Rosiglitazone maleateÂ has been evaluated for safety in a single, active-controlled trial of pediatric patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in which 99 were treated with rosiglitazone maleate and 101 were treated with metformin. The most common adverse reactions (&gt;10%) without regard to causality for eitherÂ rosiglitazone maleateÂ or metformin were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17% versus 14%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4% versus 11%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (3% versus 12%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1% versus 13%). In this study, one case of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> was reported in the metformin group. In addition, there were 3 patients in the rosiglitazone group who had FPG of âˆ¼300 mg/dL, 2+ <span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span>, and an elevated <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_a8900871-1bc1-d1b2-6f9f-1686aeffb638"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2</span> Laboratory Abnormalities</h2>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_b1ae91bb-4dfd-9f2c-a025-5f87437fad2f"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">Hematologic</span></h3>
<p class="First">Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with AVANDIA (mean decreases in individual studies as much as 1.0Â g/dL hemoglobin and as much as 3.3% hematocrit). The changes occurred primarily during the first 3Â months following initiation of therapy with AVANDIA or following a dose increase in AVANDIA. The time course and magnitude of decreases were similar in patients treated with a combination of AVANDIA and other hypoglycemic agents or monotherapy with AVANDIA. Pre-treatment levels of hemoglobin and hematocrit were lower in patients in metformin combination studies and may have contributed to the higher reporting rate of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. In a single study in pediatric patients, decreases in hemoglobin and hematocrit (mean decreases of 0.29Â g/dL and 0.95%, respectively) were reported. Small decreases in hemoglobin and hematocrit have also been reported in pediatric patients treated with AVANDIA. White blood cell counts also decreased slightly in adult patients treated with AVANDIA. Decreases in hematologic parameters may be related to increased plasma volume observed with treatment with AVANDIA.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6a94bd60-aff4-43c0-44bf-ca4ec79693ae"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Bold">Lipids</span></h3>
<p class="First">Changes in serum lipids have been observed following treatment withÂ rosiglitazone maleateÂ in adults <span class="Italics">[see <a href="#LINK_58d0f484-a0bc-ddad-dcff-e06f6725f67f">Clinical Pharmacology (12.2)</a>Â ]</span>. Small changes in serum lipid parameters were reported in children treated withÂ rosiglitazone maleateÂ for 24Â weeks.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_043b1904-4622-3b45-3db1-0035e3486a2b"></a><a name="section-6.2.3"></a><p></p>
<h3><span class="Bold">Serum Transaminase Levels</span></h3>
<p class="First">In pre-approval clinical studies in 4,598Â patients treated withÂ rosiglitazone maleateÂ (3,600Â patient-years of exposure) and in a long-term 4- to 6-year study in 1,456 patients treated withÂ rosiglitazone maleateÂ (4,954 patient-years exposure), there was no evidence of drug-induced hepatotoxicity.</p>
<p>In pre-approval controlled trials, 0.2% of patients treated withÂ rosiglitazone maleateÂ had elevations in ALT &gt;3X the upper limit of normal compared to 0.2% on placebo and 0.5% on active comparators. The ALT elevations in patients treated withÂ rosiglitazone maleateÂ were reversible. <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> was found in 0.3% of patients treated withÂ rosiglitazone maleateÂ compared with 0.9% treated with placebo and 1% in patients treated with active comparators. In pre-approval clinical trials, there were no cases of idiosyncratic drug reactions leading to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.<span class="Italics"> [See <a href="#LINK_3007c3b3-1d56-55e4-c4cd-d88a96d20e37">Warnings and Precautions (5.6).]</a>Â </span></p>
<p>In the 4- to 6-year ADOPT trial, patients treated withÂ rosiglitazone maleateÂ (4,954 patient-years exposure), glyburide (4,244 patient-years exposure), or metformin (4,906 patient-years exposure), as monotherapy, had the same rate of ALT increase to &gt;3X upper limit of normal (0.3Â per 100 patient-years exposure). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_ce7eb3fd-fd58-6515-1d53-15c7a4d7db6e"></a><a name="section-6.3"></a><p></p>
<h2>
<span class="Bold">6.3</span> Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of rosiglitazone maleate. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.</p>
<p>In patients receiving thiazolidinedione therapy, serious adverse events with or without a fatal outcome, potentially related to volume expansion (e.g., <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>) have been reported <span class="Italics">[see <a href="#LINK_26ee64f2-2713-fa29-4275-1d97b7251ae5">Boxed WarningÂ </a>Â and <span class="Italics"><a href="#LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544">Warnings and Precautions (5.1)]</a></span><a href="#LINK_709ef9ce-8ac5-0e99-4be8-3397ce1e1544">.</a>Â </span></p>
<p>There are postmarketing reports withÂ rosiglitazone maleateÂ of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic enzyme elevations to 3 or more times the upper limit of normal, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> with and without fatal outcome, although causality has not been established.</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> have been reported rarely.</p>
<p>Reports of new onset or worsening <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> with decreased visual acuity have also been received <span class="Italics">[see <span class="Italics"><a href="#LINK_0132b100-cea3-4588-8298-b68a0e1092b5">Warnings and Precautions (5.7)]</a></span><a href="#LINK_0132b100-cea3-4588-8298-b68a0e1092b5">.</a>Â </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d8dc4481-3310-a46b-e605-b82857df7a7b"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span> DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_69fbfbe3-ac86-448b-b4a1-e90767bacde7"></a><a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.1</span> CYP2C8 Inhibitors and Inducers</h2>
<p class="First">An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatment may be needed based upon clinical response. <span class="Italics">[See <a href="#LINK_c1c4b007-d6d4-4188-7d8f-ff98b08fe650">Clinical Pharmacology (12.4).]</a>Â </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_59554614-77a5-5f2c-29da-0fea7a65737e"></a><a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span> USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_f91f98d1-5bbc-c249-db3d-dab583e5d15e"></a><a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1</span> Pregnancy</h2>
<p class="First">Pregnancy Category C.<br>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may be decreased with good metabolic control. It is essential for patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or history of <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> to maintain good metabolic control before conception and throughout pregnancy. Careful monitoring of glucose control is essential in such patients. Most experts recommend that insulin monotherapy be used during pregnancy to maintain blood glucose levels as close to normal as possible.</p>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_9ffdd413-32e6-4a33-e4b8-69da7d172508"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Human Data</span></h3>
<p class="First">Rosiglitazone has been reported to cross the human placenta and be detectable in fetal tissue. The clinical significance of these findings is unknown. There are no adequate and well-controlled studies in pregnant women.Â rosiglitazone maleateÂ should not be used during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_d12fe06b-0118-40e6-90a0-f3acb3211acb"></a><a name="section-8.1.2"></a><p></p>
<h3><span class="Bold">Animal Studies</span></h3>
<p class="First">There was no effect on implantation or the embryo with rosiglitazone treatment during early pregnancy in rats, but treatment during mid-late gestation was associated with <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> in both rats and rabbits. <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> was not observed at doses up to 3Â mg/kg in rats and 100Â mg/kg in rabbits (approximately 20 and 75Â times human AUC at the maximum recommended human daily dose, respectively). Rosiglitazone caused placental pathology in rats (3Â mg/kg/day). Treatment of rats during gestation through lactation reduced litter size, neonatal viability, and postnatal growth, with <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> reversible after puberty. For effects on the placenta, embryo/fetus, and offspring, the no-effect dose was 0.2Â mg/kg/day in rats and 15 mg/kg/day in rabbits. These no-effect levels are approximately 4Â times human AUC at the maximum recommended human daily dose. Rosiglitazone reduced the number of uterine implantations and live offspring when juvenile female rats were treated at 40Â mg/kg/day from 27Â days of age through to sexual maturity (approximately 68Â times human AUC at the maximum recommended daily dose). The no-effect level was 2Â mg/kg/day (approximately 4Â times human AUC at the maximum recommended daily dose). There was no effect on pre- or post-natal survival or growth.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_bda4cfef-4f9f-c206-350e-dbc664350c0c"></a><a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.2</span> Labor and Delivery</h2>
<p class="First">The effect of rosiglitazone on labor and delivery in humans is not known.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_778cd6c7-d456-7061-da27-8b5b06693ad8"></a><a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.3</span> Nursing Mothers</h2>
<p class="First">Drug-related material was detected in milk from lactating rats. It is not known whetherÂ rosiglitazone maleateÂ is excreted in human milk. Because many drugs are excreted in human milk,Â rosiglitazone maleateÂ should not be administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ef02fbcb-cdca-0db2-2e37-4d15a5e4d63d"></a><a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.4</span> Pediatric Use</h2>
<p class="First">After placebo run-in including diet counseling, children with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, aged 10 to 17Â years and with a baseline mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) of 33Â kg/m<span class="Sup">2</span>, were randomized to treatment with 2Â mg twice daily ofÂ rosiglitazone maleateÂ (nÂ =Â 99) or 500Â mg twice daily of metformin (nÂ =Â 101) in a 24-week, double-blind clinical trial. As expected, FPG decreased in patients naÃ¯ve to <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication (nÂ =Â 104) and increased in patients withdrawn from prior medication (usually metformin) (nÂ =Â 90) during the run-in period. After at least 8Â weeks of treatment, 49% of patients treated withÂ rosiglitazone maleateÂ and 55% of metformin-treated patients had their dose doubled if FPG &gt;126Â mg/dL. For the overall intent-to-treat population, at weekÂ 24, the mean change from baseline in HbA1c was -0.14% withÂ rosiglitazone maleateÂ and -0.49% with metformin. There was an insufficient number of patients in this study to establish statistically whether these observed mean treatment effects were similar or different. Treatment effects differed for patients naÃ¯ve to therapy with antidiabetic drugs and for patients previously treated with antidiabetic therapy (Table 6).</p>
<table frame="border" rules="all">
<caption><span>Table 6. Week 24 FPG and HbA1c Change From Baseline Last-Observation-Carried Forward in Children With Baseline HbA1c &gt;6.5%</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" colspan="2" valign="top">Â <span class="Bold">NaÃ¯ve Patients</span>
</td>
<td align="center" colspan="2" valign="top">Â <span class="Bold">Previously-Treated Patients</span>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First"><span class="Bold">Metformin</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Rosiglitazone</span></p></td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Metformin</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Rosiglitazone</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â N = 40</td>
<td align="center" valign="top">Â  N = 45</td>
<td align="center" valign="top">Â N = 43</td>
<td align="center" valign="top">Â N = 32</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top">Â 170</td>
<td align="center" valign="top">Â 165</td>
<td align="center" valign="top">Â 221</td>
<td align="center" valign="top"><p class="First">205</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â -21</td>
<td align="center" valign="top">Â -11</td>
<td align="center" valign="top">Â -33</td>
<td align="center" valign="top">Â -5</td>
</tr>
<tr>
<td valign="top">Adjusted treatment difference<span class="Sup">*</span> (rosiglitazoneâ€“metformin)<span class="Sup">â€ </span> (95% CI)</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â 8<p class="First">(-15, 30)</p>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â 21<p class="First">(-9, 51)</p>
</td>
</tr>
<tr>
<td valign="top">% of patients with â‰¥30 mg/dL decrease from baseline</td>
<td align="center" valign="top">Â 43%</td>
<td align="center" valign="top">Â 27%</td>
<td align="center" valign="top">Â 44%</td>
<td align="center" valign="top">Â 28%</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 8.3</td>
<td align="center" valign="top">Â 8.2</td>
<td align="center" valign="top">Â 8.8</td>
<td align="center" valign="top">Â 8.5</td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â -0.7</td>
<td align="center" valign="top"><p class="First">-0.5</p></td>
<td align="center" valign="top">Â -0.4</td>
<td align="center" valign="top">Â 0.1</td>
</tr>
<tr>
<td valign="top"><p class="First">Adjusted treatment difference<span class="Sup">*</span> (rosiglitazoneâ€“metformin)<span class="Sup">â€ </span> (95% CI)</p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â 0.2<p class="First">(-0.6, 0.9)</p>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â 0.5<p class="First">(-0.2, 1.3)</p>
</td>
</tr>
<tr class="Last">
<td valign="top">Â % of patients with â‰¥0.7% decrease from baseline</td>
<td align="center" valign="top"><p class="First">63%</p></td>
<td align="center" valign="top">Â 52%</td>
<td align="center" valign="top">Â 54%</td>
<td align="center" valign="top"><p class="First">31%</p></td>
</tr>
</tbody>
<tbody class="Headless">
<tr class="First"><td>
<span class="Sup">*</span> Change from baseline means are least squares means adjusting for baseline HbA1c, gender, and region.</td></tr>
<tr class="Last"><td><p class="First"><span class="Sup">â€ </span> Positive values for the difference favor metformin.</p></td></tr>
</tbody>
</table>
<p>Treatment differences depended on baseline BMI or weight such that the effects ofÂ rosiglitazone maleateÂ and metformin appeared more closely comparable among heavier patients. The median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 2.8Â kg with rosiglitazone and 0.2Â kg with metformin <span class="Italics">[see <a href="#LINK_00c9e447-1728-48a5-c3b2-ea3d0efb73ae">Warnings and Precautions (5.4)</a>Â ]</span>. Fifty-four percent of patients treated with rosiglitazone and 32% of patients treated with metformin gained â‰¥2Â kg, and 33% of patients treated with rosiglitazone and 7% of patients treated with metformin gained â‰¥5Â kg on study.</p>
<p>Adverse events observed in this study are described in <span class="Italics"><a href="#LINK_5bcf47ee-3dfc-4992-1ef7-2b1485b987e1">Adverse Reactions (6.1</a></span>Â <span class="Italics">)</span>.</p>
<div class="Figure">
<img alt="Figure 3 - Mean HbA1c Over Time in a 24-Week Study of Rosiglitazone Maleate and Metformin in Pediatric Patients â€” Drug-NaÃ¯ve Subgroup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-3.jpg"><p class="MultiMediaCaption">Figure 3. Mean HbA1c Over Time in a 24-Week Study of Rosiglitazone Maleate and Metformin in Pediatric Patients â€” Drug-NaÃ¯ve Subgroup</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_62d94675-6b0c-abe6-b939-4e9eacb2655d"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.5</span> Geriatric Use</h2>
<p class="First">Results of the population pharmacokinetic analysis showed that age does not significantly affect the pharmacokinetics of rosiglitazone <span class="Italics">[see <a href="#LINK_24e5708b-2668-6b2a-f15f-3a19160f0b01">Clinical Pharmacology (12.3)</a>Â ]</span>. Therefore, no dosage adjustments are required for the elderly. In controlled clinical trials, no overall differences in safety and effectiveness between older (â‰¥65 years) and younger (&lt;65 years) patients were observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_f3ae93cd-b7da-92b9-c056-16e60e83f08e"></a><a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span> OVERDOSAGE</h1>
<p class="First">Limited data are available with regard to overdosage in humans. In clinical studies in volunteers,Â rosiglitazone maleateÂ has been administered at single oral doses of up to 20Â mg and was well-tolerated. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive treatment should be initiated as dictated by the patientâ€™s clinical status.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_286c1564-2f39-d255-5982-e18e7cdb9194"></a><a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span> DESCRIPTION</h1>
<p class="First">Rosiglitazone maleateÂ is an oral antidiabetic agent which acts primarily by increasing iinsulin sensitivity.Â RosiglitazoneÂ maleateÂ improves glycemic control while reducing circulating insulin levels.</p>
<p>Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.</p>
<p>Chemically, rosiglitazone maleate is (Â±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (<span class="Italics">Z</span>)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. The structural formula of rosiglitazone maleate is:</p>
<div class="Figure">
<img alt="Rosiglitazone Maleate Tablets - Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-4.jpg"><p class="MultiMediaCaption">Structural Formula</p>
</div>
<p>The molecular formula is C<span class="Sub">18</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">3</span>Sâ€¢C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>. Rosiglitazone maleate is a white to off-white solid with a melting point range of 122Â° to 123Â°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1. It is readily soluble in ethanol and a buffered aqueous solution with pH of 2.3; solubility decreases with increasing pH in the physiological range.Â  Each film-coated tablet contains rosiglitazone maleate equivalent to rosiglitazone, 2 mg, 4 mg or 8 mg, for oral administration.<br>Inactive ingredients are:Â  Lactose monohydrate, lechithinm, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3350, polyvinyl alcohol, red iron oxide, sodium starch glycolate type A, talc, titanium dioxide.Â  The 4 mg tablet also contains FD&amp;C yellow No, 6 aluminum lake and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_ea22d72b-6c98-b673-ee5b-01d0f15f9ea6"></a><a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span> CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_c66334e5-ff58-342a-297f-f7a54d0c37c8"></a><a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1</span> Mechanism of Action</h2>
<p class="First">Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARÎ³). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARÎ³ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARÎ³-responsive genes also participate in the regulation of fatty acid metabolism.</p>
<p><span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">Insulin resistance</span> is a common feature characterizing the pathogenesis of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The antidiabetic activity of rosiglitazone has been demonstrated in animal models of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in which <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and/or impaired glucose tolerance is a consequence of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span> in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.</p>
<p>In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulinâ€™s action in the liver, muscle, and adipose tissues. Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in animal models of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and/or impaired glucose tolerance.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_58d0f484-a0bc-ddad-dcff-e06f6725f67f"></a><a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2</span> Pharmacodynamics</h2>
<p class="First">Patients with lipid abnormalities were not excluded from clinical trials of Rosiglitazone maleate. In all 26-week controlled trials, across the recommended dose range, rosiglitazone maleate as monotherapy was associated with increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL, and HDL and decreases in free fatty acids. These changes were statistically significantly different from placebo or glyburide controls (Table 7).</p>
<p>Increases in LDL occurred primarily during the first 1 to 2Â months of therapy withÂ rosiglitazone maleateÂ and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2Â months of therapy and then appeared to decrease over time. Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids. At baseline, weekÂ 26, and weekÂ 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for rosiglitazone maleate 4Â mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9. The differences in change from baseline betweenÂ rosiglitazone maleateÂ and glyburide at weekÂ 52 were statistically significant.</p>
<p>The pattern of LDL and HDL changes following therapy withÂ rosiglitazone maleateÂ in combination with other hypoglycemic agents were generally similar to those seen withÂ rosiglitazone maleateÂ in monotherapy.</p>
<p>The changes in triglycerides during therapy with rosiglitazone maleateÂ were variable and were generally not statistically different from placebo or glyburide controls.</p>
<table frame="border" rules="all">
<caption><span>Table 7. Summary of Mean Lipid Changes in 26-Week Placebo-Controlled and 52-Week Glyburide-Controlled Monotherapy Studies</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" colspan="3" valign="top">
<p class="First"><span class="Bold">Placebo-Controlled Studies</span></p>
<p><span class="Bold">Week 26</span></p>
</td>
<td align="center" colspan="4" valign="top">Â <span class="Bold">Glyburide-Controlled Study</span><p class="First"><span class="Bold">Week 26 and Week 52</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Placebo</span></p>
</td>
<td align="center" colspan="2" valign="top">Â <p class="First"><span class="Bold">Rosiglitazone<br>maleate</span></p>
</td>
<td align="center" colspan="2" valign="top">Â <p class="First"><span class="Bold">Glyburide Titration</span></p>
</td>
<td align="center" colspan="2" valign="top">Â <p class="First"><span class="Bold">Rosiglitazone <br>maleate Â 8 mg</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â <p class="First">4 mg daily<span class="Sup">*</span></p>
</td>
<td align="center" valign="top">Â <p class="First">8 mg daily<span class="Sup">*</span></p>
</td>
<td align="center" valign="top">Â <p class="First">Wk 26</p>
</td>
<td align="center" valign="top">Â <p class="First">Wk 52</p>
</td>
<td align="center" valign="top">Â <p class="First">Wk 26</p>
</td>
<td align="center" valign="top">Â <p class="First">Wk 52</p>
</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Free fatty acids</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">N</td>
<td align="center" valign="top"><p class="First">207</p></td>
<td align="center" valign="top"><p class="First">428</p></td>
<td align="center" valign="top">Â 436</td>
<td align="center" valign="top"><p class="First">181</p></td>
<td align="center" valign="top"><p class="First">168</p></td>
<td align="center" valign="top"><p class="First">166</p></td>
<td align="center" valign="top"><p class="First">145</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">18.1</p></td>
<td align="center" valign="top">Â 17.5</td>
<td align="center" valign="top">Â 17.9</td>
<td align="center" valign="top">Â 26.4</td>
<td align="center" valign="top">Â 26.4</td>
<td align="center" valign="top">Â 26.9</td>
<td align="center" valign="top">Â 26.6</td>
</tr>
<tr>
<td valign="top"><p class="First">% Change from baseline (mean)</p></td>
<td align="center" valign="top">Â +0.2%</td>
<td align="center" valign="top">Â -7.8%</td>
<td align="center" valign="top">Â -14.7%</td>
<td align="center" valign="top">Â -2.4%</td>
<td align="center" valign="top">Â -4.7%</td>
<td align="center" valign="top">Â -20.8%</td>
<td align="center" valign="top">Â -21.5%</td>
</tr>
<tr>
<td valign="top"><span class="Bold">LDL</span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">N</td>
<td align="center" valign="top">Â 190</td>
<td align="center" valign="top">Â 400</td>
<td align="center" valign="top">Â 374</td>
<td align="center" valign="top"><p class="First">175</p></td>
<td align="center" valign="top">Â 160</td>
<td align="center" valign="top"><p class="First">161</p></td>
<td align="center" valign="top">Â 133</td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 123.7</td>
<td align="center" valign="top">Â 126.8</td>
<td align="center" valign="top">Â 125.3</td>
<td align="center" valign="top"><p class="First">142.7</p></td>
<td align="center" valign="top">Â 141.9</td>
<td align="center" valign="top">Â 142.1</td>
<td align="center" valign="top"><p class="First">142.1</p></td>
</tr>
<tr>
<td valign="top"><p class="First">% Change from baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">+4.8%</p></td>
<td align="center" valign="top"><p class="First">+14.1%</p></td>
<td align="center" valign="top">Â +18.6%</td>
<td align="center" valign="top">Â -0.9%</td>
<td align="center" valign="top">Â -0.5%</td>
<td align="center" valign="top">Â +11.9%</td>
<td align="center" valign="top">Â +12.1%</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HDL</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">N</p></td>
<td align="center" valign="top">Â 208</td>
<td align="center" valign="top">429</td>
<td align="center" valign="top">Â 436</td>
<td align="center" valign="top"><p class="First">184</p></td>
<td align="center" valign="top">Â 170</td>
<td align="center" valign="top">Â 170</td>
<td align="center" valign="top">Â 145</td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top">Â 44.1</td>
<td align="center" valign="top">44.4</td>
<td align="center" valign="top">Â 43.0</td>
<td align="center" valign="top">47.2</td>
<td align="center" valign="top">Â 47.7</td>
<td align="center" valign="top">Â 48.4</td>
<td align="center" valign="top">Â 48.3</td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">% Change from baseline (mean)</p></td>
<td align="center" valign="top">Â +8.0%</td>
<td align="center" valign="top"><p class="First">+11.4%</p></td>
<td align="center" valign="top">+14.2%</td>
<td align="center" valign="top">Â +4.3%</td>
<td align="center" valign="top">Â +8.7%</td>
<td align="center" valign="top">Â +14.0%</td>
<td align="center" valign="top">Â +18.5%</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td>
<span class="Sup">*</span> Once daily and twice daily dosing groups were combined.</td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_24e5708b-2668-6b2a-f15f-3a19160f0b01"></a><a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3</span> Pharmacokinetics</h2>
<p class="First">Maximum plasma concentration (C<span class="Sub">max</span>) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (TableÂ 8). The elimination half-life is 3 to 4Â hours and is independent of dose.</p>
<table frame="border" rules="all">
<caption><span>Table 8. Mean (SD) Pharmacokinetic Parameters for Rosiglitazone Following Single Oral Doses (NÂ =Â 32)</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â <span class="Bold">Parameter</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">1 mg</span></p>
<p><span class="Bold">Fasting</span></p>
</td>
<td align="center" valign="top">Â <span class="Bold">2Â mg</span><p class="First"><span class="Bold">Fasting</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">8 mg</span></p>
<p><span class="Bold">Fasting</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">8 mg</span></p>
<p><span class="Bold">Fed</span></p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">AUC<span class="Sub">0-inf</span></p>
<p>[ngâ€¢hr/mL]</p>
</td>
<td align="center" valign="top">Â <p class="First">358</p>
<p>(112)</p>
</td>
<td align="center" valign="top">Â <p class="First">733</p>
<p>(184)</p>
</td>
<td align="center" valign="top">Â <p class="First">2,971</p>
<p>(730)</p>
</td>
<td align="center" valign="top">Â <p class="First">2,890</p>
<p>(795)</p>
</td>
</tr>
<tr>
<td valign="top">C<span class="Sub">max</span><p class="First">[ng/mL]</p>
</td>
<td align="center" valign="top">Â <p class="First">76</p>
<p>(13)</p>
</td>
<td align="center" valign="top">Â <p class="First">156</p>
<p>(42)</p>
</td>
<td align="center" valign="top">Â <p class="First">598</p>
<p>(117)</p>
</td>
<td align="center" valign="top">Â <p class="First">432</p>
<p>(92)</p>
</td>
</tr>
<tr>
<td valign="top">Half-life<p class="First">[hr]</p>
</td>
<td align="center" valign="top">Â <p class="First">3.16</p>
<p>(0.72)</p>
</td>
<td align="center" valign="top">Â <p class="First">3.15</p>
<p>(0.39)</p>
</td>
<td align="center" valign="top">Â <p class="First">3.37</p>
<p>(0.63)</p>
</td>
<td align="center" valign="top">Â <p class="First">3.59</p>
<p>(0.70)</p>
</td>
</tr>
<tr class="Last">
<td valign="top">CL/F<span class="Sup">*</span><p class="First">[L/hr]</p>
</td>
<td align="center" valign="top">Â <p class="First">3.03</p>
<p>(0.87)</p>
</td>
<td align="center" valign="top">Â <p class="First">2.89</p>
<p>(0.71)</p>
</td>
<td align="center" valign="top">Â <p class="First">2.85</p>
<p>(0.69)</p>
</td>
<td align="center" valign="top">Â <p class="First">2.97</p>
<p>(0.81)</p>
</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td>Â <span class="Sup">*</span> CL/FÂ =Â Oral clearance.</td></tr></tbody>
</table>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_befb0e1a-df77-4237-daa5-d281446f3e62"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1Â hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in C<span class="Sub">max</span> and a delay in T<span class="Sub">max</span> (1.75Â hours). These changes are not likely to be clinically significant; therefore,Â rosiglitazone maleateÂ may be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_00751deb-1fd8-43e3-39b1-b1a2f3cd92fe"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_56aff9e3-bcda-4cf9-22a5-56e3a29b6c4c"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine. The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.</p>
<p>In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_be037eea-fc5f-7b0d-1d3f-c849cfb3e018"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold">Excretion</span></h3>
<p class="First">Following oral or intravenous administration of [<span class="Sup">14</span>C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [<span class="Sup">14</span>C]related material ranged from 103 to 158Â hours.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_8b5e5a0e-a8be-dbb0-f992-ba37105ac9fb"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold"><span class="Underline">Population Pharmacokinetics in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></span></h3>
<p class="First">Population pharmacokinetic analyses from 3 large clinical trials including 642Â men and 405Â women with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (aged 35 to 80Â years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption. Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 to 150Â kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and&lt;2.3-fold, respectively. Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_bbe5ac42-1195-9d84-69a3-98b4b864bc4b"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_5e50c29b-80ef-dd77-d97b-4d9a01ff50b6"></a><a name="section-11.3.6.1"></a><p></p>
<h4><span class="Bold">Geriatric</span></h4>
<p class="First">Results of the population pharmacokinetic analysis (nÂ =Â 716&lt;65Â years; nÂ =Â 331 â‰¥65Â years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_296a62b4-22f7-4931-95a5-24072f896c33"></a><a name="section-11.3.6.2"></a><p></p>
<h4>Gender</h4>
<p class="First">Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (nÂ =Â 405) was approximately 6% lower compared to male patients of the same body weight (nÂ =Â 642).</p>
<p>As monotherapy and in combination with metformin,Â rosiglitazone maleateÂ improved glycemic control in both males and females. In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.</p>
<p>In monotherapy studies, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident. For a given body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI), females tend to have a greater fat <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> than males. Since the molecular target PPARÎ³ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to rosiglitazone maleateÂ in females. Since therapy should be individualized, no dose adjustments are necessary based on gender alone.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_68965779-b8dd-471d-cd9b-e702d53d41ab"></a><a name="section-11.3.6.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h4>
<p class="First">Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects. As a result, unbound C<span class="Sub">max</span> and AUC<span class="Sub">0-inf</span> were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects.</p>
<p>Therapy withÂ rosiglitazone maleateÂ should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline <span class="Italics">[see <span class="Italics"><a href="#LINK_3007c3b3-1d56-55e4-c4cd-d88a96d20e37">Warnings and Precautions (5.6)]</a></span><a href="#LINK_3007c3b3-1d56-55e4-c4cd-d88a96d20e37">.</a>Â </span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_add467e5-7309-4d3a-a783-de084dd6f658"></a><a name="section-11.3.6.4"></a><p></p>
<h4><span class="Bold">Pediatric</span></h4>
<p class="First">Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17Â years (weights ranging from 35 to 178.3Â kg). Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively. These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_b7ef66e5-127d-46b6-00be-954c03590f60"></a><a name="section-11.3.6.5"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h4>
<p class="First">There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in hemodialysis-dependent patients compared to subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving rosiglitazone maleate. Since metformin is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, coadministration of metformin withÂ rosiglitazone maleateÂ is contraindicated in these patients.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_45fde410-18e2-42aa-c7ad-eb535f512e68"></a><a name="section-11.3.6.6"></a><p></p>
<h4><span class="Bold">Race</span></h4>
<p class="First">Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c1c4b007-d6d4-4188-7d8f-ff98b08fe650"></a><a name="section-11.4"></a><p></p>
<h2>
<span class="Bold">12.4</span> Drug-Drug Interactions</h2>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c1f67f63-f0b8-476f-838b-e35817345809"></a><a name="section-11.4.1"></a><p></p>
<h3><span class="Bold">Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450</span></h3>
<p class="First">In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9. rosiglitazone maleate (4Â mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_cb8d1435-06ab-4284-89a8-4cdefd0aceab"></a><a name="section-11.4.1.1"></a><p></p>
<h4><span class="Bold"><span class="Italics">Gemfibrozil</span></span></h4>
<p class="First">Concomitant administration of gemfibrozil (600Â mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4Â mg once daily) for 7Â days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4Â mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced <span class="Italics">[see <a href="#LINK_69fbfbe3-ac86-448b-b4a1-e90767bacde7">Drug Interactions (7.1)</a>Â ]</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_d7f6d9c7-ff48-4db0-3788-5fd6d02ec42b"></a><a name="section-11.4.1.2"></a><p></p>
<h4><span class="Bold"><span class="Italics">Rifampin</span></span></h4>
<p class="First">Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone <span class="Italics">[see <span class="Italics"><a href="#LINK_69fbfbe3-ac86-448b-b4a1-e90767bacde7">Drug Interactions (7.1)]</a></span><a href="#LINK_69fbfbe3-ac86-448b-b4a1-e90767bacde7">.</a>Â </span><span class="Sup">4</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_bf199837-dbd0-406f-7ba4-bcf4396e2259"></a><a name="section-11.4.2"></a><p></p>
<h3><span class="Bold"><span class="Underline">Glyburide</span></span></h3>
<p class="First">Rosiglitazone maleateÂ (2Â mg twice daily) taken concomitantly with glyburide (3.75 to 10Â mg/day) for 7Â days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of rosiglitazone maleate(8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and C<span class="Sub">max</span> of approximately 30%. In Japanese subjects, glyburide AUC and C<span class="Sub">max</span> slightly increased following coadministration of rosiglitazone maleate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_88211e9e-0661-4106-86b0-6600f8734caf"></a><a name="section-11.4.3"></a><p></p>
<h3><span class="Bold">Glimepiride</span></h3>
<p class="First">Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of rosiglitazone maleate. No clinically significant reductions in glimepiride AUC and C<span class="Sub">max</span> were observed after repeat doses ofÂ rosiglitazone maleate Â (8 mg once daily) for 8 days in healthy adult subjects.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fc16bb28-440b-4cb8-e283-faa34056f63e"></a><a name="section-11.4.4"></a><p></p>
<h3><span class="Bold">Metformin</span></h3>
<p class="First">Concurrent administration ofÂ rosiglitazone maleateÂ (2Â mg twice daily) and metformin (500Â mg twice daily) in healthy volunteers for 4Â days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_3f75c884-dea6-4746-7e99-0e05bf180398"></a><a name="section-11.4.5"></a><p></p>
<h3><span class="Bold">Acarbose</span></h3>
<p class="First">Coadministration of acarbose (100Â mg three times daily) for 7Â days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of rosiglitazone maleate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c2ad13bf-5886-46fd-fb9e-ed0b49c64137"></a><a name="section-11.4.6"></a><p></p>
<h3><span class="Bold">Digoxin</span></h3>
<p class="First">Repeat oral dosing ofÂ rosiglitazone maleateÂ (8Â mg once daily) for 14Â days did not alter the steady-state pharmacokinetics of digoxin (0.375Â mg once daily) in healthy volunteers.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c5fc723b-9043-4119-06bc-396b27d8c991"></a><a name="section-11.4.7"></a><p></p>
<h3><span class="Bold">Warfarin</span></h3>
<p class="First">Repeat dosing withÂ rosigllitazone maleateÂ had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c0db049e-e427-475c-f69b-e8fdfd9af4fa"></a><a name="section-11.4.8"></a><p></p>
<h3><span class="Bold">Ethanol</span></h3>
<p class="First">A single administration of a moderate amount of alcohol did not increase the risk of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus patients treated with rosiglitazone maleate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_91f09fff-ad41-47e9-bc96-85d567b4bbf1"></a><a name="section-11.4.9"></a><p></p>
<h3><span class="Bold">Ranitidine</span></h3>
<p class="First">Pretreatment with ranitidine (150Â mg twice daily for 4Â days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_9b581dd4-52ce-39a9-d633-0d43b8c5417f"></a><a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span> NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_9f4c471a-9bbe-0b8d-3b72-260ce0b48dfa"></a><a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1</span> Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_bc596548-2e96-443b-0888-49f261cb4f42"></a><a name="section-12.1.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">A 2-year carcinogenicity study was conducted in Charles River CD-1 mice at doses of 0.4, 1.5, and 6Â mg/kg/day in the diet (highest dose equivalent to approximately 12Â times human AUC at the maximum recommended human daily dose). Sprague-Dawley rats were dosed for 2Â years by oral gavage at doses of 0.05, 0.3, and 2Â mg/kg/day (highest dose equivalent to approximately 10 and 20Â times human AUC at the maximum recommended human daily dose for male and female rats, respectively).</p>
<p>Rosiglitazone was not carcinogenic in the mouse. There was an increase in incidence of adipose <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the mouse at doses â‰¥1.5Â mg/kg/day (approximately 2Â times human AUC at the maximum recommended human daily dose). In rats, there was a significant increase in the incidence of benign adipose tissue tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipomas</span>) at doses â‰¥0.3Â mg/kg/day (approximately 2Â times human AUC at the maximum recommended human daily dose). These proliferative changes in both species are considered due to the persistent pharmacological overstimulation of adipose tissue.</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_294ddac5-326a-4bbb-40ad-aefd8e52ebe7"></a><a name="section-12.1.2"></a><p></p>
<h3><span class="Bold">Mutagenesis</span></h3>
<p class="First">Rosiglitazone was not mutagenic or clastogenic in the in vitro bacterial assays for gene mutation, the in vitro chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, the in vivo mouse micronucleus test, and the in vivo<span class="Italics">/</span>in vitro rat UDS assay. There was a small (about 2-fold) increase in mutation in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay in the presence of metabolic activation.</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_0a82567b-10c7-1ecb-8aa8-a06ec1c1a349"></a><a name="section-12.1.3"></a><p></p>
<h3><span class="Bold">Impairment of Fertility</span></h3>
<p class="First">Rosiglitazone had no effects on mating or fertility of male rats given up to 40Â mg/kg/day (approximately 116Â times human AUC at the maximum recommended human daily dose). Rosiglitazone altered estrous cyclicity (2Â mg/kg/day) and reduced fertility (40Â mg/kg/day) of female rats in association with lower plasma levels of progesterone and estradiol (approximately 20 and 200Â times human AUC at the maximum recommended human daily dose, respectively). No such effects were noted at 0.2Â mg/kg/day (approximately 3Â times human AUC at the maximum recommended human daily dose). In juvenile rats dosed from 27Â days of age through to sexual maturity (at up to 40Â mg/kg/day), there was no effect on male reproductive performance, or on estrous cyclicity, mating performance or pregnancy incidence in females (approximately 68Â times human AUC at the maximum recommended human daily dose). In monkeys, rosiglitazone (0.6Â and 4.6Â mg/kg/day; approximately 3 and 15Â times human AUC at the maximum recommended human daily dose, respectively) diminished the follicular phase rise in serum estradiol with consequential reduction in the luteinizing hormone surge, lower luteal phase progesterone levels, and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. The mechanism for these effects appears to be direct inhibition of ovarian steroidogenesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_aebf015f-07ec-d5d0-aca6-bfd877bc41d6"></a><a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.2</span> Animal Toxicology</h2>
<p class="First">Heart weights were increased in mice (3Â mg/kg/day), rats (5Â mg/kg/day), and dogs (2Â mg/kg/day) with rosiglitazone treatments (approximately 5, 22, and 2Â times human AUC at the maximum recommended human daily dose, respectively). Effects in juvenile rats were consistent with those seen in adults. Morphometric measurement indicated that there was <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> in cardiac ventricular tissues, which may be due to increased heart work as a result of plasma volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_938b7c76-1dda-c8ce-a760-e4f0858adcca"></a><a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span> CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1cdd11fd-33e1-4301-1b7e-f971f309bde7"></a><a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1</span> Monotherapy</h2>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_3c960689-9571-233b-7528-31b3c7bc140e"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Bold">Short Term Clinical Studies</span></h3>
<p class="First">A total of 2,315Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, previously treated with diet alone or antidiabetic medication(s), were treated with rosilitazone maleate as monotherapy in 6 double-blind studies, which included two 26-week placebo-controlled studies, one 52-week glyburide-controlled study, and 3 placebo-controlled dose-ranging studies of 8 to 12Â weeks duration. Previous antidiabetic medication(s) were withdrawn and patients entered a 2 to 4Â week placebo run-in period prior to randomization.</p>
<p>Two 26-week, double-blind, placebo-controlled trials, in patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (nÂ =Â 1,401) with inadequate glycemic control (mean baseline FPG approximately 228Â mg/dL [101 to 425Â mg/dL] and mean baseline HbA1c 8.9% [5.2% to 16.2%]), were conducted. Treatment with AVANDIA produced statistically significant improvements in FPG and HbA1c compared to baseline and relative to placebo. Data from one of these studies are summarized in Table 9.</p>
<table frame="border" rules="all">
<caption><span>Table 9. Glycemic Parameters in a 26-Week Placebo-Controlled Trial</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td rowspan="2" valign="top">Â </td>
<td align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
<td align="center" colspan="2" valign="top">Â <span class="Bold">Rosiglitazone maleate</span>
</td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Rosiglitazone maleate</span></p></td>
</tr>
<tr>
<td align="center" valign="top">Â <span class="Bold">4 mg once daily</span>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">2 mg twice daily</span></p></td>
<td align="center" valign="top">Â <span class="Bold">8 mg once daily</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4 mg twice daily</span>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First">N = 173</p></td>
<td align="center" valign="top"><p class="First">N = 180</p></td>
<td align="center" valign="top">Â N = 186</td>
<td align="center" valign="top">Â N = 181</td>
<td align="center" valign="top">Â N = 187</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 225</td>
<td align="center" valign="top">Â 229</td>
<td align="center" valign="top">Â 225</td>
<td align="center" valign="top">Â 228</td>
<td align="center" valign="top">Â 228</td>
</tr>
<tr>
<td valign="top">Change from baseline (mean)</td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">-25</p></td>
<td align="center" valign="top">Â -35</td>
<td align="center" valign="top">Â -42</td>
<td align="center" valign="top">Â -55</td>
</tr>
<tr>
<td valign="top">Difference from placebo (adjusted mean)</td>
<td align="center" valign="top">Â â€“</td>
<td align="center" valign="top"><p class="First">-31<span class="Sup">*</span></p></td>
<td align="center" valign="top">Â -43<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -49<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -62<span class="Sup">*</span>
</td>
</tr>
<tr>
<td valign="top">% of patients with â‰¥30 mg/dL decrease from baseline</td>
<td align="center" valign="top"><p class="First">19%</p></td>
<td align="center" valign="top">Â 45%</td>
<td align="center" valign="top">Â 54%</td>
<td align="center" valign="top">Â 58%</td>
<td align="center" valign="top">Â 70%</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top"><p class="First">9.0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â 0.8</td>
<td align="center" valign="top">Â 0.0</td>
<td align="center" valign="top">Â -0.1</td>
<td align="center" valign="top">Â -0.3</td>
<td align="center" valign="top">Â -0.7</td>
</tr>
<tr>
<td valign="top">Difference from placebo (adjusted mean)</td>
<td align="center" valign="top">Â â€“</td>
<td align="center" valign="top">Â -0.8<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -0.9<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -1.1<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -1.5<span class="Sup">*</span>
</td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">% of patients with â‰¥0.7% decrease from baseline</p></td>
<td align="center" valign="top">Â 9%</td>
<td align="center" valign="top">Â 28%</td>
<td align="center" valign="top">Â 29%</td>
<td align="center" valign="top">Â 39%</td>
<td align="center" valign="top"><p class="First">54%</p></td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td><p class="First"><span class="Sup">*</span>p&lt;0.0001 compared to placebo.</p></td></tr></tbody>
</table>
<p>When administered at the same total daily dose,Â rosiglitazone maleateÂ was generally more effective in reducing FPG and HbA1c when administered in divided doses twice daily compared to once daily doses. However, for HbA1c, the difference between the 4Â mg once daily and 2Â mg twice daily doses was not statistically significant.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_88923196-fd0b-f2e7-ec42-d551ceffc34e"></a><a name="section-13.1.2"></a><p></p>
<h3>Long Term Clinical Studies</h3>
<p class="First">Long-term maintenance of effect was evaluated in a 52-week, double-blind, glyburide-controlled trial in patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Patients were randomized to treatment with rosiglitazone maleate 2Â mg twice daily (NÂ =Â 195) or rosiglitazone maleate 4Â mg twice daily (NÂ =Â 189) or glyburide (NÂ =Â 202) for 52Â weeks. Patients receiving glyburide were given an initial dosage of either 2.5Â mg/day or 5.0Â mg/day. The dosage was then titrated in 2.5Â mg/day increments over the next 12Â weeks, to a maximum dosage of 15.0Â mg/day in order to optimize glycemic control. Thereafter the glyburide dose was kept constant.</p>
<p>The median titrated dose of glyburide was 7.5Â mg. All treatments resulted in a statistically significant improvement in glycemic control from baseline (Figure 4 and Figure 5). At the end of week 52, the reduction from baseline in FPG and HbA1c was -40.8 mg/dL and -0.53% with rosiglitazone maleate 4Â mg twice daily; -25.4Â mg/dL and -0.27% with rosiglitazone maleate 2Â mg twice daily; and -30.0Â mg/dL and -0.72% with glyburide. For HbA1c, the difference between rosiglitazone maleate 4Â mg twice daily and glyburide was not statistically significant at weekÂ 52. The initial <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FPG with glyburide was greater than with rosiglitazone maleate; however, this effect was less durable over time. The improvement in glycemic control seen with rosiglitazone maleate 4 mg twice daily at weekÂ 26 was maintained through weekÂ 52 of the study.</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <img alt="Figure 4 - Chart/Graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-5.jpg"><p class="MultiMediaCaptionNotCentered">Figure 4 Mean FPG Over Time in a 52-Week Glyburide-Controlled Study</p></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <img alt="Figure 5 - Graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce&amp;name=rosiglitazone-maleate-tablets-6.jpg"><p class="MultiMediaCaptionNotCentered">Figure 5 Mean HbA1c Over Time in a 52 Week-Gkyburide-Controlled Study</p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in 12.1% of glyburide-treated patients versus 0.5% (2Â mg twice daily) and 1.6% (4Â mg twice daily) of patients treated with rosiglitazone maleate. The improvements in glycemic control were associated with a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 1.75Â kg and 2.95Â kg for patients treated with 2Â mg and 4Â mg twice daily of rosiglitazone maleate, respectively, versus 1.9Â kg in glyburide-treated patients. In patients treated with rosiglitazone maleate, C-peptide, insulin, pro-insulin, and pro-insulin split products were significantly reduced in a dose-ordered fashion, compared to an increase in the glyburide-treated patients.</p>
<p>A <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Outcome Progression Trial (ADOPT) was a multicenter, double-blind, controlled trial (nÂ =Â 4,351) conducted over 4 to 6 years to compare the safety and efficacy of rosiglitazone maleate, metformin, and glyburide monotherapy in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (â‰¤3 years) inadequately controlled with diet and exercise. The mean age of patients in this trial was 57Â years and the majority of patients (83%) had no known history of cardiovascular disease. The mean baseline FPG and HbA1c were 152Â mg/dL and 7.4%, respectively. Patients were randomized to receive either rosiglitazone maleate 4Â mg once daily, glyburide 2.5Â mg once daily, or metformin 500Â mg once daily, and doses were titrated to optimal glycemic control up to a maximum of 4Â mg twice daily for rosiglitazone maleate, 7.5Â mg twice daily for glyburide, and 1,000Â mg twice daily for metformin. The primary efficacy outcome was time to consecutive FPG &gt;180Â mg/dL after at least 6Â weeks of treatment at the maximum tolerated dose of study medication or time to inadequate glycemic control, as determined by an independent adjudication committee.</p>
<p>The cumulative incidence of the primary efficacy outcome at 5Â years was 15% with rosiglitazone maleate, 21% with metformin, and 34% with glyburide (hazard ratio 0.68 [95% CI 0.55, 0.85] versus metformin, HR 0.37 [95% CI 0.30, 0.45] versus glyburide).</p>
<p>Cardiovascular and adverse event data (including effects on body weight and bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>) from ADOPT for rosiglitazone maleate, metformin, and glyburide are described in Warnings and Precautions (5.2, 5.5, and 5.8) and Adverse Reactions (6.1), respectively. As with all medications, efficacy results must be considered together with safety information to assess the potential benefit and risk for an individual patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_37d8a1cc-c407-874d-b5d5-9000bef6faf4"></a><a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">14.2</span> Combination With Metformin or Sulfonylurea</h2>
<p class="First">The addition of rosiglitazone maleate to either metformin or sulfonylurea resulted in significant reductions in <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> compared to either of these agents alone. These results are consistent with an additive effect on glycemic control whenÂ rosiglitazone maleateÂ is used as combination therapy.</p>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_672a43d5-021f-5742-6f97-90cd1ee17ca7"></a><a name="section-13.2.1"></a><p></p>
<h3>Combination with Metformin</h3>
<p class="First">A total of 670 patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in two 26-week, randomized, double-blind, placebo/active-controlled studies designed to assess the efficacy of rosiglitazone maleate in combination with metformin. rosiglitazone maleate, administered in either once daily or twice daily dosing regimens, was added to the therapy of patients who were inadequately controlled on a maximum dose (2.5Â grams/day) of metformin.</p>
<p>In one study, patients inadequately controlled on 2.5Â grams/day of metformin (mean baseline FPG 216Â mg/dL and mean baseline HbA1c 8.8%) were randomized to receive 4Â mg of rosiglitazone maleate once daily, 8Â mg of rosiglitazone maleate once daily, or placebo in addition to metformin. A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of metformin and 4Â mg of rosiglitazone maleate once daily and 8Â mg of rosiglitazone maleate once daily, versus patients continued on metformin alone (Table 10).</p>
<table frame="border" rules="all">
<caption><span>Table 10. Glycemic Parameters in a 26-Week Combination Study of Rosiglitazone Maleate Plus Metformin</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" valign="top">Â <span class="Bold">Metformin</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Rosiglitazone Maleate</span></p>
<p><span class="Bold">4 mg once daily + metformin</span></p>
</td>
<td align="center" valign="top">Â <span class="Bold">Rosiglitazone Maleate</span><p class="First"><span class="Bold">8 mg once daily + metformin</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First">N = 113</p></td>
<td align="center" valign="top"><p class="First">N = 116</p></td>
<td align="center" valign="top">Â N = 110</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">214</p></td>
<td align="center" valign="top"><p class="First">215</p></td>
<td align="center" valign="top"><p class="First">220</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top">Â -33</td>
<td align="center" valign="top"><p class="First">-48</p></td>
</tr>
<tr>
<td valign="top">Â Difference from metformin alone (adjusted mean)</td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top">Â -40<span class="Sup">*</span>
</td>
<td align="center" valign="top"><p class="First">-53<span class="Sup">*</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">% of patients with â‰¥30 mg/dL decrease from baseline</p></td>
<td align="center" valign="top"><p class="First">20%</p></td>
<td align="center" valign="top">Â 45%</td>
<td align="center" valign="top"><p class="First">61%</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 8.6</td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top">Â 8.9</td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">0.5</p></td>
<td align="center" valign="top">Â -0.6</td>
<td align="center" valign="top">Â -0.8</td>
</tr>
<tr>
<td valign="top">Difference from metformin alone (adjusted mean)</td>
<td align="center" valign="top">Â â€“</td>
<td align="center" valign="top">Â  -1.0<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â -1.2<span class="Sup">*</span>
</td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">% of patients with â‰¥0.7% decrease from baseline</p></td>
<td align="center" valign="top"><p class="First">11%</p></td>
<td align="center" valign="top">Â 45%</td>
<td align="center" valign="top"><p class="First">52%</p></td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td><p class="First"><span class="Sup">*</span> p&lt;0.0001 compared to metformin.</p></td></tr></tbody>
</table>
<p>In a second 26-week study, patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on 2.5Â grams/day of metformin who were randomized to receive the combination of rosiglitazone maleate 4Â mg twice daily and metformin (NÂ =Â 105) showed a statistically significant improvement in glycemic control with a mean treatment effect for FPG of -56Â mg/dL and a mean treatment effect for HbA1c of -0.8% over metformin alone. The combination of metformin and rosiglitazone maleate resulted in lower levels of FPG and HbA1c than either agent alone.</p>
<p>Patients who were inadequately controlled on a maximum dose (2.5Â grams/day) of metformin and who were switched to monotherapy with rosiglitazone maleate demonstrated loss of glycemic control, as evidenced by increases in FPG and HbA1c. In this group, increases in LDL and VLDL were also seen.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_cfe4b47b-2ecb-9a39-1c22-4fa3b9f37760"></a><a name="section-13.2.2"></a><p></p>
<h3>Combination with Sulfonylurea</h3>
<p class="First">A total of 3,457Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in ten 24- to 26-week randomized, double-blind, placebo/active-controlled studies and one 2-year double-blind, active-controlled study in elderly patients designed to assess the efficacy and safety of rosiglitazone maleate in combination with a sulfonylurea. rosiglitazone maleate 2Â mg, 4Â mg, or 8Â mg daily, was administered either once daily (3 studies) or in divided doses twice daily (7Â studies), to patients inadequately controlled on a submaximal or maximal dose of sulfonylurea.</p>
<p>In these studies, the combination of rosiglitazone maleate 4Â mg or 8Â mg daily (administered as single or twice daily divided doses) and a sulfonylurea significantly reduced FPG and HbA1c compared to placebo plus sulfonylurea or further up-titrationof the sulfonylurea. Table 11 shows pooled data for 8 studies in which rosiglitazone maleate added to sulfonylurea was compared to placebo plus sulfonylurea.</p>
<table frame="border" rules="all">
<caption><span>Table 11. Glycemic Parameters in 24- to 26-Week Combination Studies of Rosiglitazone Maleate Plus Sulfonylurea</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â <span class="Bold">Twice Daily Divided Dosing </span><p class="First"><span class="Bold">(5 Studies)</span></p>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">Sulfonylurea</span></p></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Rosiglitazone Maleate</span></p>
<p><span class="Bold">2 mg twice daily + sulfonylurea</span></p>
</td>
<td align="center" valign="top">Â  S<span class="Bold">ulfonylurea</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Rosiglitazone M</span></p>
<p><span class="Bold">4 mg twice daily + sulfonylurea</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First">N = 397</p></td>
<td align="center" valign="top">Â N = 497</td>
<td align="center" valign="top">Â N = 248</td>
<td align="center" valign="top">Â N = 346</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">204</p></td>
<td align="center" valign="top"><p class="First">198</p></td>
<td align="center" valign="top"><p class="First">188</p></td>
<td align="center" valign="top"><p class="First">187</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
<td align="center" valign="top"><p class="First">-29</p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">-43</p></td>
</tr>
<tr>
<td valign="top">Difference from sulfonylurea alone (adjusted mean)</td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top">Â -42<span class="Sup">*</span>
</td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top"><p class="First">-53<span class="Sup">*</span></p></td>
</tr>
<tr>
<td valign="top">% of patients with â‰¥30Â mg/dL decrease from baseline</td>
<td align="center" valign="top"><p class="First">17%</p></td>
<td align="center" valign="top">Â 49%</td>
<td align="center" valign="top"><p class="First">15%</p></td>
<td align="center" valign="top"><p class="First">61%</p></td>
</tr>
<tr>
<td valign="top"><span class="Bold">HbA1c (%)</span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 9.4</td>
<td align="center" valign="top">Â 9.5</td>
<td align="center" valign="top">Â 9.3</td>
<td align="center" valign="top"><p class="First">9.6</p></td>
</tr>
<tr>
<td valign="top">Change from baseline (mean)</td>
<td align="center" valign="top"><p class="First">0.2</p></td>
<td align="center" valign="top"><p class="First">-1.0</p></td>
<td align="center" valign="top">Â 0.0</td>
<td align="center" valign="top">Â -1.6</td>
</tr>
<tr>
<td valign="top"><p class="First">Difference from sulfonylurea alone (adjusted mean)</p></td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top">Â -1.1<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â â€“</td>
<td align="center" valign="top"><p class="First">-1.4<span class="Sup">*</span></p></td>
</tr>
<tr>
<td valign="top">% of patients with â‰¥0.7% decrease from baseline</td>
<td align="center" valign="top">Â 21%</td>
<td align="center" valign="top">Â 60%</td>
<td align="center" valign="top"><p class="First">23%</p></td>
<td align="center" valign="top">Â 75%</td>
</tr>
<tr>
<td valign="top">
<span class="Bold">Once Daily Dosing</span><p class="First"><span class="Bold">(3 Studies)</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Sulfonylurea</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">rosiglitazone maleate</span></p>
<p><span class="Bold">4 mg once daily + sulfonylurea</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Sulfonylurea</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">rosiglitazone maleate</span></p>
<p><span class="Bold">8 mg once daily + sulfonylurea</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top"><p class="First">N = 172</p></td>
<td align="center" valign="top">Â N = 172</td>
<td align="center" valign="top"><p class="First">N = 173</p></td>
<td align="center" valign="top"><p class="First">N = 176</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top"><p class="First">Baseline (mean)</p></td>
<td align="center" valign="top"><p class="First">198</p></td>
<td align="center" valign="top"><p class="First">206</p></td>
<td align="center" valign="top">Â 188</td>
<td align="center" valign="top"><p class="First">192</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â 17</td>
<td align="center" valign="top"><p class="First">-25</p></td>
<td align="center" valign="top">Â 17</td>
<td align="center" valign="top">Â -43</td>
</tr>
<tr>
<td valign="top">Difference from sulfonylurea alone (adjusted mean)</td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top">Â -47<span class="Sup">*</span>
</td>
<td align="center" valign="top">Â â€“</td>
<td align="center" valign="top"><p class="First">-66<span class="Sup">*</span></p></td>
</tr>
<tr>
<td valign="top">% of patients with â‰¥30 mg/dL decrease from baseline</td>
<td align="center" valign="top"><p class="First">17%</p></td>
<td align="center" valign="top">Â 48%</td>
<td align="center" valign="top">Â 19%</td>
<td align="center" valign="top">Â 55%</td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 8.6</td>
<td align="center" valign="top">Â 8.8</td>
<td align="center" valign="top">Â 8.9</td>
<td align="center" valign="top"><p class="First">8.9</p></td>
</tr>
<tr>
<td valign="top">Change from baseline (mean)</td>
<td align="center" valign="top">Â 0.4</td>
<td align="center" valign="top">Â -0.5</td>
<td align="center" valign="top">Â 0.1</td>
<td align="center" valign="top">Â -1.2</td>
</tr>
<tr>
<td valign="top"><p class="First">Difference from sulfonylurea alone (adjusted mean)</p></td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top"><p class="First">-0.9<span class="Sup">*</span></p></td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top"><p class="First">-1.4<span class="Sup">*</span></p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">% of patients with â‰¥0.7% decrease from baseline</p></td>
<td align="center" valign="top">Â 11%</td>
<td align="center" valign="top">Â 36%</td>
<td align="center" valign="top">Â 20%</td>
<td align="center" valign="top">Â 68%</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td>
<span class="Sup">*</span> p&lt;0.0001 compared to sulfonylurea alone.</td></tr></tbody>
</table>
<p>One of the 24- to 26-week studies included patients who were inadequately controlled on maximal doses of glyburide and switched to 4Â mg of rosiglitazone maleate daily as monotherapy; in this group, loss of glycemic control was demonstrated, as evidenced by increases in FPG and HbA1c.</p>
<p>In a 2-year double-blind study, elderly patients (aged 59 to 89Â years) on half-maximal sulfonylurea (glipizide 10Â mg twice daily) were randomized to the addition of rosiglitazone maleate (nÂ =Â 115, 4Â mg once daily to 8Â mg as needed) or to continued up-titration of glipizide (nÂ =Â 110), to a maximum of 20Â mg twice daily. Mean baseline FPG and HbA1c were 157 mg/dL and 7.72%, respectively, for the rosiglitazone maleate plus glipizide arm and 159 mg/dL and 7.65%, respectively, for the glipizide up-titration arm. Loss of glycemic control (FPG â‰¥180Â mg/dL) occurred in a significantly lower proportion of patients (2%) on rosiglitazone maleate plus glipizide compared to patients in the glipizide up-titration arm (28.7%). About 78% of the patients on combination therapy completed the 2Â years of therapy while only 51% completed on glipizide monotherapy. The effect of combination therapy on FPG and HbA1c was durable over the 2-year study period, with patients achieving a mean of 132 mg/dL for FPG and a mean of 6.98% for HbA1c compared to no change on the glipizide arm.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_828ddd97-d255-0e32-da30-6fae9aef066f"></a><a name="section-13.3"></a><p></p>
<h2>
<span class="Bold">14.3</span> Combination With Sulfonylurea Plus Metformin</h2>
<p class="First">In two 24- to 26-week, double-blind, placebo-controlled, studies designed to assess the efficacy and safety ofÂ rosiglitazone maleateÂ in combination with sulfonylurea plus metformin,Â rosiglitazone maleateÂ 4Â mg or 8Â mg daily, was administered in divided doses twice daily, to patients inadequately controlled on submaximal (10Â mg) and maximal (20Â mg) doses of glyburide and maximal dose of metformin (2Â g/day). A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of sulfonylurea plus metformin and 4Â mg ofÂ rosiglitazoneÂ maleateÂ and 8Â mg of rosiglitazone maleateÂ versus patients continued on sulfonylurea plus metformin, as shown in Table 12.</p>
<table frame="border" rules="all">
<caption><span>TableÂ 12. Glycemic Parameters in a 26-Week Combination Study ofÂ RosiglitazoneÂ MaleateÂ Plus Sulfonylurea and Metformin</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top">Â </td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Sulfonylurea + metformin</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Rosiglitazone<br>maleate <br></span><span class="Bold">2 mg twice daily + sulfonylurea + metformin</span></p>
</td>
<td align="center" valign="top">Â <p class="First"><span class="Bold">Rosiglitazone<br>maleate<br></span><span class="Bold">4 mg twice daily + sulfonylurea + metformin</span></p>
</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â N = 273</td>
<td align="center" valign="top">Â N = 276</td>
<td align="center" valign="top">Â N = 277</td>
</tr>
<tr>
<td valign="top"><span class="Bold">FPG (mg/dL)</span></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top"><p class="First">189</p></td>
<td align="center" valign="top"><p class="First">190</p></td>
<td align="center" valign="top"><p class="First">192</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â 14</td>
<td align="center" valign="top">Â -19</td>
<td align="center" valign="top"><p class="First">-40</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Difference from sulfonylurea plus metformin (adjusted mean)</p></td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top"><p class="First">-30<span class="Sup">*</span></p></td>
<td align="center" valign="top"><p class="First">-52<span class="Sup">*</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">% of patients with â‰¥30 mg/dL decrease from baseline</p></td>
<td align="center" valign="top"><p class="First">16%</p></td>
<td align="center" valign="top">Â 46%</td>
<td align="center" valign="top"><p class="First">62%</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Baseline (mean)</td>
<td align="center" valign="top">Â 8.7</td>
<td align="center" valign="top">Â 8.6</td>
<td align="center" valign="top">Â 8.7</td>
</tr>
<tr>
<td valign="top"><p class="First">Change from baseline (mean)</p></td>
<td align="center" valign="top">Â 0.2</td>
<td align="center" valign="top">-0.4</td>
<td align="center" valign="top">-0.9</td>
</tr>
<tr>
<td valign="top"><p class="First">Difference from sulfonylurea plus metformin (adjusted mean)</p></td>
<td align="center" valign="top"><p class="First">â€“</p></td>
<td align="center" valign="top"><p class="First">-0.6<span class="Sup">*</span></p></td>
<td align="center" valign="top"><p class="First">-1.1<span class="Sup">*</span></p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">% of patients with â‰¥0.7% decrease from baseline</p></td>
<td align="center" valign="top">Â 16%</td>
<td align="center" valign="top">Â 39%</td>
<td align="center" valign="top">Â 63%</td>
</tr>
</tbody>
<tbody class="Headless"><tr class="First Last"><td><p class="First"><span class="Sup">*</span> p&lt;0.0001 compared to placebo.</p></td></tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_3d049c64-742d-9dc8-f308-45ed7f940a14"></a><a name="section-14"></a><p></p>
<h1>
<span class="Bold">15</span> REFERENCES</h1>
<ul class="Disk">
<li><p class="First">Food and Drug Administration Briefing Document. Joint meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees. July 30, 2007.</p></li>
<li><p class="First">DREAM Trial Investigators. Effect of rosiglitazone on the frequency of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in patients with impaired glucose tolerance or <span class="product-label-link" type="condition" conceptid="4308509" conceptname="Impaired fasting glycaemia">impaired fasting glucose</span>: a randomised controlled trial. <span class="Italics">Lancet</span> 2006;368:1096-1105.</p></li>
<li><p class="First">Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes â€“ an interim analysis. <span class="Italics">NEJM</span> 2007;357:1-11.</p></li>
<li><p class="First">Park JY, Kim KA, Kang MH, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. <span class="Italics">Clin Pharmacol Ther</span> 2004;75:157-162.</p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_0a8dc515-fa0a-bca7-0b93-939316795e4f"></a><a name="section-15"></a><p></p>
<h1>
<span class="Bold">16</span> HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Tablets:</span>Â  each oval film-coated tablet contains rosiglitazone as the maleate as follows:</p>
<p>2 mg - Pink oval film coated tablets, engraved with W41; supplied in bottles of 30, 100 and 500</p>
<p>4 mgÂ - Orange oval film coated tablets, engraved with W42; supplied in bottles of 30, 100 and 500.</p>
<p>8 mg - Brick-red oval film coated tablets, engraved with W43, supplied in bottles of 30, 100 and 500.</p>
<p>Store at 25Â°C (77Â°F); excursions 15Â° to 30Â°C (59Â° to 86Â°F). Dispense in a tight, light-resistant container.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_967677fb-64d7-383f-58b0-209700b97501"></a><a name="section-16"></a><p></p>
<h1>
<span class="Bold">17</span> PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bab54fde-a37a-4ea3-959c-fb5823792874"></a><a name="section-16.1"></a><p></p>
<h2>
<span class="Bold">17.1</span> Patient Advice</h2>
<p class="First">Patients should be informed of the following:</p>
<ul class="Disk">
<li><p class="First">Rosiglitazone maleate is not recommended for patients with symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p></li>
<li><p class="First">Patients with more severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA Class 3 or 4) cannot startÂ Rosiglitazone maleate as the risks exceed any potential benefits in such patients.</p></li>
<li><p class="First">Results of a set of clinical studies suggest that treatment withÂ Rosiglitazone MaleateÂ is associated with an increased risk for myocardial ischemic events, such as angina or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>), especially in patients taking insulin or nitrates. Because this risk has not been confirmed or excluded in different long-term trials, definitive conclusions regarding this risk await completion of an adequately-designed cardiovascular outcome study.</p></li>
<li><p class="First">RosiglitazoneÂ maleate is not recommended for patients who are taking nitrates or insulin.</p></li>
<li><p class="First">There are multiple medications available to treat type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and each patient with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is unique. The benefits and risks of each available <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication should be taken into account when choosing a particular <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication for a given patient.</p></li>
<li><p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Rosiglitazone maleateor any other oral antidiabetic drug.</p></li>
<li><p class="First">Management of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should include diet control. Caloric restriction, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and exercise are essential for the proper treatment of the diabetic patient because they help improve insulin sensitivity. This is important not only in the primary treatment of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, but in maintaining the efficacy of drug therapy.</p></li>
<li><p class="First">It is important to adhere to dietary instructions and to regularly have blood glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> tested. It can take 2Â weeks to see a reduction in blood glucose and 2 to 3Â months to see the full effect of Rosiglitazone maleat.</p></li>
<li><p class="First">Blood will be drawn to check their liver function prior to the start of therapy and periodically thereafter per the clinical judgment of the healthcare professional. Patients with unexplained symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or dark urine should immediately report these symptoms to their physician.</p></li>
<li><p class="First">Patients who experience an unusually rapid increase in weight or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or who develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or other symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while onÂ Rosiglitazone maleateÂ should immediately report these symptoms to their physician.</p></li>
<li><p class="First">Rosiglitazone maleateÂ can be taken with or without meals.</p></li>
<li><p class="First">When usingÂ Rosiglitazoe maleateÂ in combination with other hypoglycemic agents, the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and their family members.</p></li>
<li><p class="First">Therapy with Rosiglitazone maleate, like other thiazolidinediones, may result in ovulation in some Rosiglitazone maleate<span class="Italics">[see <a href="#LINK_b1bcbd7e-bdc2-452d-0da7-625bbc701fbb">Warnings and Precautions (5.10)Â </a>Â and <a href="#LINK_f91f98d1-5bbc-c249-db3d-dab583e5d15e">Use in Specific Populations (8.1</a>Â )]</span>. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical studies so the frequency of this occurrence is not known.</p></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_18d2c7a0-b1ef-c4c6-8450-7d01370fb853"></a><a name="section-17"></a><p></p>
<h1>FDA-Approved Medication Guide</h1>
<p class="First">See separate leaflet.</p>
<p>ADVANDAMET is registered trademark of GlaxoSmithKline.</p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  MEDICATION GUIDE<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </span><span class="Bold">RosiglitazoneÂ Maleate Tablets</span></p>
<p>Read this Medication Guide carefully before you start takingÂ rosiglitazone maleateÂ and each time you get a refill. There may be new information. This information rosiglitazone maleate, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about rosiglitazone maleate tablets?</span></p>
<p>Rosiglitazone maleate tabletsÂ can cause serious side effects, including:</p>
<p><span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span></p>
<ul class="Disk">
<li><p class="First">Rosiglitazone maleate can cause your body to keep extra fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), which leads to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Extra body fluid can make some heart problems worse or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough.</p></li>
<li><p class="First">If you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, you cannot start on Rosiglitazone maleate.</p></li>
<li><p class="First">If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), even if these symptoms are not severe, Rosiglitazone maleate may not be right for you.</p></li>
</ul>
<p>Call your doctor right away if you have any of the following:</p>
<ul class="Disk">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, especially in the ankles or legs</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, especially when you lie down</p></li>
<li><p class="First">an unusually fast increase in weight</p></li>
<li><p class="First">feel unusually tired</p></li>
</ul>
<p><span class="Bold">Other heart problems</span></p>
<p>Rosiglitazone maleate may increase the risk of heart problems related to reduced blood flow to the heart. These include possible increases in the risk of heart-related <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina) or "<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>" (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). This risk seems to be higher in patients who took Rosiglitazone maleate with insulin or with nitrate medicines. Most people who take insulin or nitrate medicines should not also take Rosiglitazone maleate.</p>
<ul class="Disk">
<li><p class="First">If you have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or a feeling of <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span>, get medical help right away, no matter what <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines you are taking.</p></li>
<li><p class="First">Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have a greater risk for heart problems. It is important to work with your doctor to manage other conditions, such as high blood pressure or high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p></li>
</ul>
<p>Rosiglitazone maleate can have other serious side effects. Be sure to read the section below â€œWhat are possible side effects of Rosiglitazone maleate?â€?.</p>
<p><span class="Bold">What is Rosiglitazone maleate?</span></p>
<p>Rosiglitazone maleate is a prescription medicine used with diet and exercise to treat adults with type 2 (â€œadult-onsetâ€? or â€œnon-insulin dependentâ€?) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (â€œhigh blood sugarâ€?). Rosiglitazone maleate helps to control high blood sugar. Rosiglitazone maleate may be used alone or with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. Rosiglitazone maleate can help your body respond better to insulin made in your body. Rosiglitazone maleate does not cause your body to make more insulin. Rosiglitazone maleate can also cause serious side effects.</p>
<ul class="Disk">
<li><p class="First">In order for Rosiglitazone maleate to work best, it is very important to exercise, lose extra weight, and follow the diet recommended by your doctor.</p></li>
<li><p class="First">Rosiglitazone maleate has not been studied enough in children under 18 years of age to know if it is safe or effective in children.</p></li>
<li><p class="First">Rosiglitazone maleate is not for patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or to treat a condition called <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p></li>
</ul>
<p><span class="Bold">Who should not take Rosiglitazone maleate?</span></p>
<p>Many patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should not start taking Rosiglitazone maleate. See â€œWhat should I tell my doctor before taking Rosiglitazone maleate?â€?.</p>
<p><span class="Bold">What should I tell my doctor before taking Rosiglitazone maleate?</span></p>
<p>Before starting Rosiglitazone maleate, ask your doctor about what the choices are for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, and what the expected benefits and possible risks are for you in particular.</p>
<p>Before taking Rosiglitazone maleate, tell your doctor about all your medical conditions, including if you:</p>
<ul class="Disk">
<li><p class="First"><span class="Bold">have heart problems or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></p></li>
<li><p class="First"><span class="Bold">have type 1 (â€œjuvenileâ€?) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</span> These conditions should be treated with insulin.</p></li>
<li><p class="First"><span class="Bold">have a type of diabetic eye disease called <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span></span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the back of the eye).</p></li>
<li><p class="First"><span class="Bold">have liver problems.</span> Your doctor should do blood tests to check your liver before you start taking Rosiglitazone maleate and during treatment as needed.</p></li>
<li><p class="First"><span class="Bold">had liver problems while taking REZULIN</span><span class="Bold"><span class="Sup">Â®</span> (troglitazone), another medicine for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span></p></li>
<li><p class="First"><span class="Bold">are pregnant or plan to become pregnant.</span> Rosiglitazone maleate should not be used during pregnancy. It is not known if Rosiglitazone maleate can harm your unborn baby. You and your doctor should talk about the best way to control your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> during pregnancy. If you are a premenopausal woman (before the â€œchange of lifeâ€?) who does not have regular monthly periods, Rosiglitazone maleate may increase your chances of becoming pregnant. Talk to your doctor about birth control choices while taking Rosiglitazone maleate. Tell your doctor right away if you become pregnant while taking Rosiglitazone maleate.</p></li>
<li><p class="First"><span class="Bold">are breast-feeding or planning to breast-feed.</span> It is not known if Rosiglitazone maleate passes into breast milk. You should not use Rosiglitazone maleate while breastfeeding.</p></li>
</ul>
<p>Tell your doctor about all the medicines you take including prescription and non-prescription medicines,vitamins or herbal supplements. Rosiglitazone maleate and certain other medicines can affect each other and lead to serious side effects including high or low blood sugar, or heart problems. Especially tell your doctor if you take:</p>
<ul class="Disk">
<li><p class="First"><span class="Bold">insulin.</span></p></li>
<li><p class="First"><span class="Bold">nitrate medicines</span> such as nitroglycerin or isosorbide to treat a type of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> called angina.</p></li>
<li><p class="First"><span class="Bold">any medicines for high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or for prevention of heart disease or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></p></li>
</ul>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is alright to take Rosiglitazone maleate with other medicines.</p>
<p><span class="Bold">How should I take Rosiglitazone maleate?</span></p>
<ul class="Disk">
<li><p class="First">Take Rosiglitazone maleate exactly as prescribed. Your doctor will tell you how many tablets to take and how often. The usual daily starting dose is 4 mg a day taken one time each day or 2 mg taken two times each day. Your doctor may need to adjust your dose until your blood sugar is better controlled.</p></li>
<li><p class="First">Rosiglitazone maleate may be prescribed alone or with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. This will depend on how well your blood sugar is controlled.</p></li>
<li><p class="First">Take Rosiglitazone maleate with or without food.</p></li>
<li><p class="First">It can take 2 weeks for Rosiglitazone maleate to start lowering blood sugar. It may take 2 to 3 months to see the full effect on your blood sugar level.</p></li>
<li><p class="First">If you miss a dose of Rosiglitazone maleate, take it as soon as you remember, unless it is time to take your next dose. Take your next dose at the usual time. Do not take double doses to make up for a missed dose.</p></li>
<li><p class="First">If you take too much Rosiglitazone maleate, call your doctor or poison control center right away.</p></li>
<li><p class="First">Test your blood sugar regularly as your doctor tells you.</p></li>
<li><p class="First">Diet and exercise can help your body use its blood sugar better. It is important to stay on your recommended diet, lose extra weight, and get regular exercise while taking Rosiglitazone maleate.</p></li>
<li><p class="First">Your doctor should do blood tests to check your liver before you start Rosiglitazone maleate and during treatment as needed. Your doctor should also do regular blood sugar tests (for example, â€œA1Câ€?) to monitor your response to Rosiglitazone maleate.</p></li>
<li><p class="First">Your doctor should check your eyes regularly. Some patients have had vision changes due to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye, called <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, while taking Rosiglitazone maleate.</p></li>
</ul>
<p><span class="Bold">What are possible side effects of Rosiglitazone maleate?</span></p>
<p><span class="Bold">Rosiglitazone maleate can cause serious side effects including:</span></p>
<ul class="Disk">
<li><p class="First"><span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> See â€œWhat is the most important information I should know about Rosiglitazone maleate?â€?.</p></li>
<li><p class="First"><span class="Bold">Other heart problems.</span> Rosiglitazone maleate may increase the risk of heart problems related to reduced blood flow to the heart. These include possible increases in the risk of heart-related <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina) or "<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>" (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). See â€œWhat is the most important information I should know about Rosiglitazone maleate?â€?.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>).</span> Rosiglitazone maleate can cause <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. See â€œWhat is the most important information I should know about Rosiglitazone maleate?â€?.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>.</span> Rosiglitazone maleate can cause <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> that may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or extra body fat. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> can be a serious problem for people with certain conditions including heart problems. See â€œWhat is the most important information I should know about Rosiglitazone maleate?â€?.</p></li>
<li>
<p class="First"><span class="Bold">Liver problems.</span> It is important for your liver to be working normally when you take Rosiglitazone maleate. Your doctor should do blood tests to check your liver before you start taking Rosiglitazone maleate and during treatment as needed. Call your doctor right away if you have unexplained symptoms such as:</p>
<ul class="Circle">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></p></li>
<li><p class="First">unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></p></li>
<li><p class="First">loss of appetite</p></li>
<li><p class="First">dark urine</p></li>
<li><p class="First">yellowing of your skin or the whites of your eyes.</p></li>
</ul>
</li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span></span> (a diabetic eye disease with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye). Tell your doctor right away if you have any changes in your vision.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>,</span> usually in the hand, upper arm or foot, in females. Talk to your doctor for advice on how to keep your bones healthy.</p></li>
<li><p class="First"><span class="Bold">Low red blood cell count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>).</span></p></li>
<li><p class="First"><span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span> or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> may mean that your blood sugar is too low. This can happen if you skip meals, if you use another medicine that lowers blood sugar, or if you have certain medical problems. Call your doctor if low blood sugar levels are a problem for you.</p></li>
<li><p class="First"><span class="Bold">Ovulation</span> (release of egg from an ovary in a woman) leading to pregnancy. Ovulation may happen in premenopausal women who do not have regular monthly periods. This can increase the chance of pregnancy. See â€œWhat should I tell my doctor before taking Rosiglitazone maleate?â€?.</p></li>
</ul>
<p>The most common side effects of Rosiglitazone maleate reported in clinical trials included <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Rosiglitazone maleate?</span></p>
<ul class="Disk">
<li><p class="First">Store Rosiglitazone maleate at room temperature, 59Â° to 86Â°F (15Â° to 30Â°C). Keep Rosiglitazone maleate in the container it comes in.</p></li>
<li><p class="First">Safely, throw away Rosiglitazone maleate that is out of date or no longer needed.</p></li>
<li><p class="First">Keep Rosiglitazone maleate and all medicines out of the reach of children.</p></li>
</ul>
<p><span class="Bold">General information about Rosiglitazone maleate</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Rosiglitazone maleate for a condition for which it was not prescribed. Do not give Rosiglitazone maleate to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes important information about rosiglitazone maleate tablets.Â  If you would like more information about rosiglitazone maleate tablets that is written for helathcare professionals.Â  You can also find out more about rosiglitazone maleate tablets by calling West-ward Pharmaceutical Corp at 732-542-1191.</p>
<p><span class="Bold">What are the ingredients in Rosiglitazone maleate?</span></p>
<p>Active Ingredient: Rosiglitazone maleate.</p>
<p>Inactive Ingredients:Lactose monohydrate, lechithin, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3350, polyvinyl alcohol, red iron oxide, sodium starch glycolate type A, talc, titanium dioxide.Â  The 4 mg tablet also contains FD&amp;C yellow No. 6 aluminum lake and yellow iron oxide.</p>
<p>Always check to make sure that the medicine you are taking is the correct one.Â  Rosiglitazone maleateÂ  tablets look like this:</p>
<p>2 mg â€“ Pink oval film coated tablets, engraved with W41.</p>
<p>4 mg â€“ Orange oval film coated tablets, engraved with W42.</p>
<p>8 mg â€“ Brick red oval film coated tablets, engraved with W43.</p>
<p>REZULIN is a registered trademark of Parke-Davis Pharmaceuticals Ltd.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">West-ward Pharmaceutical Corp<br></span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Eatontown, NJÂ  07724-USA<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Distributor</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Manufactured by:Â Â <br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">Hikma Pharmaceutical</span>Â Â Â Â Â Â <br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â P.O. Box 182400<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â AmmanÂ Â  11118Â Â <br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â  JordanÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </p>
<p>Revised:Â  April 2009</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROSIGLITAZONE MALEATEÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9973</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE MALEATE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EGG PHOSPHOLIPIDS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;41</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9973-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0143-9973-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0143-9973-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078658</td>
<td class="formItem">06/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROSIGLITAZONE MALEATEÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9974</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE MALEATE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EGG PHOSPHOLIPIDS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;42</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9974-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0143-9974-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0143-9974-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078658</td>
<td class="formItem">06/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROSIGLITAZONE MALEATEÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9975</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE MALEATE</td>
<td class="formItem">8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EGG PHOSPHOLIPIDS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (brick-red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;43</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9975-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0143-9975-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0143-9975-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078658</td>
<td class="formItem">06/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c6998838-0d1a-4822-805e-9b7298e13c77</div>
<div>Set id: dd8d7ec8-79b0-4152-8789-d247c77232ce</div>
<div>Version: 2</div>
<div>Effective Time: 20090722</div>
</div>
</div>Â <div class="DistributorName">West-ward Pharmaceutical Corp</div></p>
</body></html>
